Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 847871-99-2] Lenalidomidehemihydrate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-A0003B |
| Brand: | MCE |
| CAS: | 847871-99-2 |
Overview
| MDL | MFCD28167742 |
|---|---|
| Molecular Weight | 268.27 |
| Molecular Formula | C13H14N3O3.5 |
| SMILES | O=C1N(C2C(NC(CC2)=O)=O)CC3=C(N)C=CC=C31.[0.5 H2O] |
For research use only. We do not sell to patients.
26 Publications Citing Use of MCE
- [1]Cell. 2018 Sep 20;175(1):171-185.e25.
- [2]Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.
- [3]Nat Chem Biol. 2021 Jun;17(6):711-717.
- [4]Nat Commun. 2017 May 22;8:15398.
- [5]Cell Syst. 2018 Apr 25;6(4):424-443.e7.
- [6]Elife. 2018 Aug 1;7:e38430.
- [7]Oxid Med Cell Longev. 29 Dec 2021.
- [8]Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254.
- [9]Food Chem Toxicol. 2019 Mar;125:392-402.
- [10]iScience. 19 July 2022, 104781.
- [11]Biochim Biophys Acta Mol Basis Dis. 2022 Jun 22;166472.
- [12]Front Cell Infect Microbiol. 2022 Jul 28;12:954814.
- [13]Am J Pathol. 2015 Jun;185(6):1783-94.
- [14]Oncol Rep. 2018 Jun;39(6):2873-2880.
- [15]Exp Cell Res. 2020 Aug 1;393(1):112054.
- [16]Inflammation. 2019 Feb;42(1):221-234.
- [17]Patent. US20220332776A1.
- [18]Nat Cancer. 2022 May;3(5):595-613.
- [19]Patent. US20210379039A1.
- [20]University of Washington. The Columbian College of Arts and Sciences. August 31, 2021.
- [21]ACS Pharmacol Transl Sci. 2021 Feb 26.
- [22]bioRxiv. April.
- [23]Patent. US20180263995A1.
- [24]Patent. US20170360780A1.
- [25]Faculty of Science, Masaryk University. Department of Experimental Biology.2014.
- [26]Harvard Medical School LINCS LIBRARY
Summary
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN) , and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells [1] [2] .
IC50 & Target
|
Cereblon
|
In Vitro
Lenalidomide is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. Lenalidomide downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells [2] . Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC 50 values of ~30 μM, ~3 μM and ~3 μM, respectively, These reduced CRBN expression cells (U266-CRBN 60 and U266-CRBN 75 ) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10 μM [3] . Lenalidomide, a thalidomide analog, functions as a molecular glue between the human E3 ubiquitin ligase cereblon and CKIα is shown to induce the ubiquitination and degradation of this kinase, thus presumably killing leukemic cells by p53 activation [5] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The toxicity of Lenalidomide doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03050450 | Johns Hopkins All Children´s Hospital |
Central Nervous System Tumors
|
August 10, 2016 | Phase 1 |
| NCT03015792 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
March 10, 2017 | Phase 1|Phase 2 |
| NCT01169298 | Celgene |
Adult T-cell Leukemia-Lymphoma|Peripheral T-cell Lymphoma
|
July 1, 2010 | Phase 1 |
| NCT03290950 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Multiple Myeloma
|
September 25, 2017 | Phase 2 |
| NCT02431208 | Hoffmann-La Roche |
Multiple Myeloma
|
July 22, 2015 | Phase 1 |
| NCT01442714 | Stanford University|Celgene Corporation |
Leukemia|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)
|
August 2011 | Phase 2 |
| NCT04223661 | Tyler Davis, MD, FACP|Janssen Scientific Affairs, LLC|Indiana Institute for Medical Research|Indiana University |
Multiple Myeloma
|
December 6, 2021 | Phase 2 |
| NCT00564889 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 2007 | Phase 2 |
| NCT03019640 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Indolent Adult Non-Hodgkin Lymphoma
|
October 10, 2017 | Phase 2 |
| NCT03113695 | University of California, San Diego |
Richter´s Syndrome|CLL
|
December 20, 2017 | Phase 1 |
| NCT01301820 | French Innovative Leukemia Organisation|Celgene Corporation |
Acute Myeloid Leukemia
|
January 2011 | Phase 2 |
| NCT02279394 | Dana-Farber Cancer Institute|Bristol-Myers Squibb|Celgene|Blood Cancer Research Partnership|Multiple Myeloma Research Consortium|The Leukemia and Lymphoma Society |
Smoldering Myeloma|Smoldering Multiple Myeloma
|
December 11, 2014 | Phase 2 |
| NCT00378105 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
September 2006 | Phase 1|Phase 2 |
| NCT01938001 | Celgene |
Lymphoma, Non-Hodgkin
|
November 21, 2013 | Phase 3 |
| NCT02142049 | Pharmacyclics LLC.|Celgene Corporation |
Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory
|
May 2014 | Phase 1|Phase 2 |
| NCT02472691 | Heinrich-Heine University, Duesseldorf|Celgene Corporation |
Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic
|
May 2015 | Phase 2 |
| NCT00971685 | Istituto Clinico Humanitas |
POEMS Syndrome
|
July 2009 | Phase 2 |
| NCT04009109 | Alliance Foundation Trials, LLC.|Janssen Scientific Affairs, LLC|Celgene Corporation|Takeda |
Myeloma, Multiple
|
October 21, 2020 | Phase 2 |
| NCT03490344 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
May 3, 2018 | Phase 2 |
| NCT03606577 | Nantes University Hospital |
Multiple Myeloma
|
July 30, 2019 | Phase 2 |
| NCT01953692 | Merck Sharp & Dohme LLC |
Myelodysplastic Syndrome|Multiple Myeloma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Primary Mediastinal B-Cell Lymphoma
|
November 22, 2013 | Phase 1 |
| NCT04217967 | Peking Union Medical College Hospital|Peking University Third Hospital|Beijing Jishuitan Hospital|Beijing Chao Yang Hospital|Xuanwu Hospital, Beijing|Peking University First Hospital|Jilin Provincial Tumor Hospital|Second Hospital of Shanxi Medical University|The First Affiliated Hospital of Shanxi Medical University|Tianjin Medical University General Hospital|The First Affiliated Hospital of Anhui Medical University |
Multiple Myeloma
|
January 3, 2020 | Phase 4 |
| NCT02281279 | Mayo Clinic|National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
October 2016 | Phase 1|Phase 2 |
| NCT03302728 | Peter MacCallum Cancer Centre, Australia |
Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Lymphoma
|
August 30, 2018 | Phase 1 |
| NCT04126200 | GlaxoSmithKline |
Multiple Myeloma
|
October 7, 2019 | Phase 1|Phase 2 |
| NCT01583283 | Celgene |
Multiple Myeloma
|
July 12, 2012 | Phase 1 |
| NCT00478959 | University Health Network, Toronto|Celgene Corporation |
Hodgkin Disease
|
December 2006 | Phase 2 |
| NCT00415116 | The Cleveland Clinic|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2004 | Phase 1 |
| NCT01555281 | Swiss Group for Clinical Cancer Research |
Multiple Myeloma
|
February 23, 2012 | Phase 1|Phase 2 |
| NCT01348919 | Cephalon|Teva Branded Pharmaceutical Products R&D, Inc. |
Multiple Myeloma
|
August 2011 | Phase 1|Phase 2 |
| NCT00772915 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 3, 2008 | Phase 2 |
| NCT03733691 | Oncotherapeutics|Takeda |
Newly Diagnosed Multiple Myeloma
|
March 1, 2019 | Phase 2 |
| NCT01062152 | Telik |
Myelodysplastic Syndrome
|
November 2009 | Phase 1 |
| NCT03891355 | Fondazione Italiana Linfomi ONLUS |
Mantle Cell Lymphoma
|
September 30, 2019 | Phase 2 |
| NCT01093183 | University of Nebraska|National Cancer Institute (NCI) |
Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer
|
March 2010 | Phase 1|Phase 2 |
| NCT02255162 | Massachusetts General Hospital|Celgene Corporation |
Acute Myeloid Leukemia (AML)|Acute Myelocytic Leukemia|Acute Myelogenous Leukemia|Acute Granulocytic Leukemia|Acute Non-Lymphocytic Leukemia
|
January 2015 | Phase 1 |
| NCT02420860 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic Cell Transplantation Recipient|Plasma Cell Myeloma
|
April 14, 2015 | Phase 2 |
| NCT03702725 | Alliance Foundation Trials, LLC.|Pharmacyclics LLC. |
Refractory Multiple Myeloma|Multiple Myeloma in Relapse|Multiple Myeloma
|
August 29, 2019 | Phase 1 |
| NCT04775550 | Omar Nadeem|Janssen, LP|Dana-Farber Cancer Institute |
High-risk Smoldering Multiple Myeloma|Multiple Myeloma
|
April 9, 2021 | Phase 2 |
| NCT00790842 | PrECOG, LLC.|Celgene |
Multiple Myeloma|Plasma Cell Neoplasm
|
January 21, 2009 | Phase 1|Phase 2 |
| NCT00910910 | Celgene |
B-Cell Chronic Lymphocytic Leukemia
|
October 13, 2009 | Phase 3 |
| NCT01645930 | Millennium Pharmaceuticals, Inc.|Takeda |
Multiple Myeloma
|
December 17, 2012 | Phase 1 |
| NCT01347944 | Celgene |
Myelodysplastic Syndrome
|
January 1, 2011 | |
| NCT01954784 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
October 7, 2013 | Phase 1 |
| NCT02516423 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|Biologics, Inc. |
Solitary Osseous Plasmacytoma
|
December 2015 | Phase 3 |
| NCT01243476 | Fundación General de la Universidad de Salamanca|Celgene Corporation |
Myelodysplastic Syndrome
|
January 2010 | Phase 3 |
| NCT00553644 | National Cancer Institute (NCI) |
Recurrent Mantle Cell Lymphoma
|
November 15, 2007 | Phase 2 |
| NCT05265975 | Antengene Corporation |
Diffuse Large B-cell Lymphoma|Indolent Non-Hodgkin Lymphoma
|
April 7, 2022 | Phase 1|Phase 2 |
| NCT01718379 | Groupe Francophone des Myelodysplasies|Celgene|Roche Pharma AG |
Myelodysplastic Syndromes
|
July 2010 | Phase 2 |
| NCT01460940 | Ohio State University Comprehensive Cancer Center|Celgene|Novartis |
Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma
|
October 13, 2011 | Phase 2 |
| NCT04663347 | Genmab|AbbVie |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma
|
November 16, 2020 | Phase 1|Phase 2 |
| NCT04096066 | Fondazione EMN Italy Onlus |
Multiple Myeloma|New Diagnosis Tumor
|
July 1, 2019 | Phase 3 |
| NCT01060384 | University of Nebraska|Celgene Corporation|GlaxoSmithKline |
Non-Hodgkin´s Lymphoma
|
March 2010 | Phase 1|Phase 2 |
| NCT04882163 | Celgene |
Lymphoma, B-Cell
|
October 10, 2021 | Phase 1|Phase 2 |
| NCT00812968 | Celgene |
Myelodysplastic Syndromes
|
September 1, 2007 | Phase 2 |
| NCT03859427 | Amgen |
Relapsed or Refractory Multiple Myeloma
|
May 8, 2019 | Phase 3 |
| NCT03433001 | Takeda |
Relapsed and+or Refractory Multiple Myeloma
|
April 2, 2018 | |
| NCT00065156 | Celgene |
Myelodysplastic Syndromes
|
June 1, 2003 | Phase 2 |
| NCT02460276 | Lund University Hospital|Celgene|Janssen, LP|Nordic Lymphoma Group |
Relapsed+Refractory Mantle Cell Lymphoma
|
April 2015 | Phase 2 |
| NCT00378209 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
August 2006 | Phase 2 |
| NCT01116193 | Institut de Cancérologie de la Loire|Celgene Corporation |
Leukemia, Lymphoid|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
January 2010 | Phase 2 |
| NCT00779922 | Poitiers University Hospital |
Multiple Myeloma|Impaired Renal Function
|
November 2008 | Phase 2 |
| NCT00507442 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Multiple Myeloma
|
August 2007 | Phase 1|Phase 2 |
| NCT00987493 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
September 2009 | Phase 1|Phase 2 |
| NCT04938297 | Henan Cancer Hospital |
Central Nervous System Lymphoma
|
May 26, 2021 | Phase 2 |
| NCT00036894 | National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
March 2002 | Phase 1 |
| NCT00840827 | Weill Medical College of Cornell University|Celgene |
Myelodysplastic Syndrome
|
December 2008 | Phase 2 |
| NCT01564537 | Millennium Pharmaceuticals, Inc.|Takeda |
Relapsed Multiple Myeloma|Refractory Multiple Myeloma
|
August 1, 2012 | Phase 3 |
| NCT03252600 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)|Bristol-Myers Squibb|Multiple Myeloma Research Consortium |
Recurrent Primary Amyloidosis
|
August 25, 2017 | Phase 2 |
| NCT04025593 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 17, 2019 | Phase 2 |
| NCT04270409 | Sanofi |
Plasma Cell Myeloma
|
June 16, 2020 | Phase 3 |
| NCT04151667 | H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
November 22, 2019 | Phase 2 |
| NCT00430365 | University Hospital, Toulouse|Intergroupe Francophone du Myelome|Celgene |
Myeloma
|
June 2006 | Phase 3 |
| NCT03168100 | University of Arkansas |
Multiple Myeloma
|
October 1, 2017 | Phase 2 |
| NCT02331368 | University of Michigan Rogel Cancer Center|Medical College of Wisconsin |
Multiple Myeloma
|
June 2015 | Phase 2 |
| NCT03412565 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2018 | Phase 2 |
| NCT00538824 | Weill Medical College of Cornell University|Celgene |
Multiple Myeloma
|
December 2007 | Phase 2 |
| NCT00843882 | National Cancer Institute (NCI) |
Anemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome
|
January 29, 2009 | Phase 3 |
| NCT05179733 | Ruijin Hospital|Wuhan Union Hospital, China|Ningbo No. 1 Hospital|National Naval Medical Center|Shanghai Fengxian District Central Hospital|YANCHENG NO.1 PEOPLE´S HOSPITAL|The First Affiliated Hospital of Nanchang University|Affiliated Hospital of Nantong University|Wuxi Branch of Ruijin Hospital|Sir Run Run Shaw Hospital|Northern Jiangsu Province People´s Hospital|The First People´s Hospital of Changde City|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Changzhou No.2 People´s Hospital|The Affiliated Hospital of Xuzhou Medical University|Huai´an First People´s Hospital|Taizhou Hospital|The First people´s Hospital of Kunshan|First Affiliated Hospital of Fujian Medical University|Huadong Hospital|Henan Provincial People´s Hospital|First Hospital of China Medical University |
Diffuse Large B-Cell Lymphoma
|
March 2, 2022 | Phase 3 |
| NCT01169337 | National Cancer Institute (NCI) |
Light Chain Deposition Disease|Smoldering Plasma Cell Myeloma
|
January 24, 2011 | Phase 2|Phase 3 |
| NCT01650701 | The Lymphoma Academic Research Organisation|Celgene Corporation |
Follicular Lymphoma
|
February 2012 | Phase 3 |
| NCT03188172 | University of Leeds|Myeloma UK|Celgene|Janssen, LP |
Multiple Myeloma
|
September 28, 2017 | Phase 2 |
| NCT00890929 | Stanford University|Celgene Corporation |
Acute Myeloid Leukemia (AML)|Adult Acute Myeloblastic Leukemia
|
April 2009 | Phase 1|Phase 2 |
| NCT00532675 | Novartis Pharmaceuticals|Novartis |
Multiple Myeloma
|
April 22, 2008 | Phase 1 |
| NCT01558167 | German CLL Study Group|Mundipharma Research GmbH & Co KG|Roche Pharma AG|Celgene |
Chronic Lymphocytic Leukemia
|
February 2011 | Phase 1|Phase 2 |
| NCT03173092 | Takeda |
Multiple Myeloma
|
September 20, 2017 | Phase 4 |
| NCT03015922 | University of Leeds|Myeloma UK|Oncolytics Biotech|Celgene Corporation |
Multiple Myeloma
|
June 5, 2017 | Phase 1 |
| NCT01036399 | University of Bologna |
Peripheral T-cell Lymphoma
|
November 2008 | Phase 2 |
| NCT02733042 | Celgene |
Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell
|
May 11, 2016 | Phase 1|Phase 2 |
| NCT00633945 | University of Pennsylvania|Celgene Corporation |
Cutaneous Lupus Erythematosus (CLE)
|
November 2007 | Not Applicable |
| NCT03104842 | Universitätsklinikum Hamburg-Eppendorf |
Multiple Myeloma
|
August 15, 2017 | Phase 2 |
| NCT01245673 | University of Pennsylvania |
Myeloma
|
May 10, 2011 | Phase 2 |
| NCT02060656 | Royal Marsden NHS Foundation Trust|Celgene Corporation |
Diffuse Large B-Cell Lymphoma
|
September 2013 | Phase 2 |
| NCT00774345 | Celgene |
B-cell Chronic Lymphocytic Leukemia
|
January 27, 2009 | Phase 3 |
| NCT01142232 | Attaya Suvannasankha|Celgene|Indiana University |
Multiple Myeloma
|
August 27, 2010 | Phase 1|Phase 2 |
| NCT04483739 | European Myeloma Network|EMN Research Italy|Sanofi|Amgen |
Multiple Myeloma
|
September 25, 2020 | Phase 3 |
| NCT00833534 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2009 | Phase 2 |
| NCT01123356 | Medical University of South Carolina|GlaxoSmithKline|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
May 2010 | Phase 2 |
| NCT01271283 | National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
December 2010 | Phase 2 |
| NCT01373229 | David Rizzieri, MD|Celgene Corporation|Genzyme, a Sanofi Company|Duke University |
Leukemia, Lymphocytic, Chronic, B-Cell
|
January 2012 | Phase 1 |
| NCT01316523 | University of California, Davis|Celgene |
Non Hodgkin´s Lymphoma
|
December 2010 | Phase 2 |
| NCT00617591 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C. |
Multiple Myeloma
|
January 2008 | Phase 2 |
| NCT05283720 | AbbVie|Genmab |
Non-Hodgkin Lymphoma
|
June 14, 2022 | Phase 2 |
| NCT02697344 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma
|
April 14, 2016 | Phase 1 |
| NCT02903381 | Dana-Farber Cancer Institute|Bristol-Myers Squibb|Multiple Myeloma Research Consortium|Blood Cancer Research Partnership |
Smoldering Multiple Myeloma
|
October 2016 | Phase 2 |
| NCT01718743 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic Cell Transplantation Recipient|Plasma Cell Myeloma
|
December 3, 2012 | Phase 2 |
| NCT01578954 | UNC Lineberger Comprehensive Cancer Center|Celgene |
Acute Myeloid Leukemia
|
June 28, 2012 | Phase 1 |
| NCT02389543 | Karyopharm Therapeutics Inc |
Multiple Myeloma
|
July 2015 | Phase 1|Phase 2 |
| NCT00727415 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Chronic Lymphocytic Leukemia
|
February 2008 | Phase 1|Phase 2 |
| NCT01056679 | University of Cologne |
Hodgkin Lymphoma
|
April 2010 | Phase 1 |
| NCT02180711 | Acerta Pharma BV|AstraZeneca |
Non Hodgkin Lymphoma
|
December 29, 2014 | Phase 1 |
| NCT00031941 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
April 2002 | Phase 1 |
| NCT04432714 | The First Affiliated Hospital with Nanjing Medical University |
DLBCL|Untreated|MYC Gene Rearrangement
|
June 9, 2020 | Phase 1|Phase 2 |
| NCT03031730 | National Cancer Institute (NCI) |
Plasmacytoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
October 27, 2017 | Phase 1 |
| NCT02874742 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 29, 2016 | Phase 2 |
| NCT00179647 | Celgene Corporation|Prologue Research International|Celgene |
Multiple Myeloma
|
September 2005 | Phase 3 |
| NCT01054196 | Weill Medical College of Cornell University|Celgene |
Multiple Myeloma
|
August 2010 | Phase 1|Phase 2 |
| NCT01307592 | Auxilio Mutuo Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 2011 | Phase 2 |
| NCT02589145 | M.D. Anderson Cancer Center|Celgene Corporation |
Lymphoma
|
June 22, 2016 | Phase 1|Phase 2 |
| NCT01829568 | National Cancer Institute (NCI)|Celgene Corporation |
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma
|
June 21, 2013 | Phase 1 |
| NCT05561387 | Southwest Oncology Group|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
December 1, 2022 | Phase 3 |
| NCT05259839 | TeneoOne Inc. |
Relapsed+Refractory Multiple Myeloma
|
October 20, 2022 | Phase 1 |
| NCT01675141 | National Cancer Institute (NCI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
August 20, 2012 | Phase 2 |
| NCT01133275 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation |
Myelodysplastic Syndrome|MDS
|
April 28, 2010 | Phase 2 |
| NCT00942578 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Metastatic Prostate Cancer
|
July 16, 2009 | Phase 2 |
| NCT04903197 | Novartis Pharmaceuticals|Novartis |
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
|
January 24, 2022 | Phase 1 |
| NCT00704691 | University of Alabama at Birmingham |
Peripheral T-cell Lymphomas|Adult T-cell Leukemia|Adult T-cell Lymphoma|Peripheral T-cell Lymphoma Unspecified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|T+Null Cell Systemic Type|Cutaneous t-Cell Lymphoma With Nodal+Visceral Disease
|
June 2008 | Early Phase 1 |
| NCT03031483 | International Extranodal Lymphoma Study Group (IELSG) |
Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
|
April 3, 2017 | Phase 2 |
| NCT03416374 | Takeda |
Relapsed and+or Refractory Multiple Myeloma
|
February 18, 2018 | Phase 4 |
| NCT01729104 | M.D. Anderson Cancer Center|Celgene|Onyx Therapeutics, Inc. |
Lymphoma
|
April 25, 2013 | Phase 1 |
| NCT04519476 | Oncotherapeutics|Karyopharm Therapeutics Inc |
Refractory Multiple Myeloma
|
November 1, 2020 | Phase 1 |
| NCT04361643 | Hospital Universitario Getafe |
COVID-19
|
October 27, 2020 | Phase 4 |
| NCT01742793 | Yale University|Peter MacCallum Cancer Centre, Australia |
Hodgkin´s Lymphoma|Mature T-cell Lymphoma|Multiple Myeloma
|
October 2012 | Phase 1 |
| NCT01242930 | Geron Corporation |
Multiple Myeloma
|
November 2010 | Phase 2 |
| NCT02206425 | Oncotherapeutics|Takeda |
Multiple Myeloma
|
September 2014 | Phase 1|Phase 2 |
| NCT05558319 | PETHEMA Foundation|Bristol-Myers Squibb|Sanofi|Adknoma|Start from scratch |
Newly Diagnosed Multiple Myeloma
|
October 2022 | Phase 3 |
| NCT04109872 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Mantle Cell Lymphoma
|
September 15, 2018 | |
| NCT00923234 | Technische Universität Dresden|Celgene Corporation |
Myelodysplastic Syndromes|Acute Myelogenous Leukemia
|
June 2009 | Phase 1 |
| NCT01091831 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
July 2009 | Phase 3 |
| NCT00109772 | Celgene Corporation|Celgene |
Complex Regional Pain Syndrome, Type I
|
February 2005 | Phase 2 |
| NCT01207921 | Washington University School of Medicine|Celgene Corporation |
Hodgkin Disease
|
April 28, 2011 | Phase 1 |
| NCT02843074 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Multiple Myeloma
|
September 21, 2016 | Phase 2 |
| NCT04113226 | Centre Hospitalier Universitaire, Amiens|cimiez hospital Nice|Institut Bergonié|groupe hospitalier public sud de l´oise|Henri Mondor University Hospital|Centre Henri Becquerel|Hôpital Charles Foix|Saint-Louis Hospital, Paris, France |
Chemotherapy|Diffuse Large B-Cell Lymphoma (DLBCL), Nos|Elderly
|
July 26, 2021 | Phase 2 |
| NCT00765245 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2008 | Phase 2 |
| NCT01079936 | M.D. Anderson Cancer Center |
Myeloma|Stem Cell Transplantation
|
March 2010 | Phase 1|Phase 2 |
| NCT01419795 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia
|
May 2012 | Phase 2 |
| NCT00792077 | M.D. Anderson Cancer Center |
Leukemia|CLL
|
November 2008 | Phase 2 |
| NCT01659658 | Millennium Pharmaceuticals, Inc.|Takeda |
Relapsed or Refractory Systemic Light Chain Amyloidosis
|
December 12, 2012 | Phase 3 |
| NCT02285062 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
January 21, 2015 | Phase 3 |
| NCT01042704 | Robert Redner, MD|Cephalon|University of Pittsburgh |
Myeloma
|
February 2008 | Phase 1 |
| NCT00412581 | M.D. Anderson Cancer Center|Celgene Corporation |
Melanoma
|
September 2005 | Phase 1 |
| NCT01553149 | National Cancer Institute (NCI) |
Neurofibromatosis Type 1|Recurrent Childhood Pilocytic Astrocytoma|Recurrent Childhood Visual Pathway Glioma
|
March 19, 2012 | Phase 2 |
| NCT05615636 | M.D. Anderson Cancer Center |
Hodgkin Lymphoma|B-Cell Lymphoma|Relapsed B-cell NHL
|
April 30, 2023 | Phase 2 |
| NCT02343042 | Karyopharm Therapeutics Inc |
Multiple Myeloma
|
October 2015 | Phase 1|Phase 2 |
| NCT00478218 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
July 2006 | Phase 2 |
| NCT05409066 | AbbVie|Genmab |
Follicular Lymphoma (FL)
|
September 20, 2022 | Phase 3 |
| NCT02911142 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Effusion Lymphoma|B-Cell Neoplasm
|
July 3, 2017 | Phase 1|Phase 2 |
| NCT05183139 | Takeda |
Multiple Myeloma
|
June 30, 2022 | Phase 4 |
| NCT00966693 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
August 25, 2009 | Phase 1|Phase 2 |
| NCT04518982 | Zhao Wang|Beijing Friendship Hospital |
CAEBV
|
August 1, 2020 | Phase 2 |
| NCT01222754 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Diffuse Intrinsic Pontine Glioma|Anaplastic Astrocytoma|High Grade Glioma
|
November 23, 2010 | Phase 1 |
| NCT00963105 | Celgene |
Relapsed or Refractory Chronic Lymphocytic Leukemia
|
October 19, 2009 | Phase 2 |
| NCT04497961 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
August 28, 2020 | Phase 2 |
| NCT00883623 | Heidelberg University|Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
Primary Amyloidosis
|
April 2009 | Phase 2 |
| NCT02252172 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 16, 2015 | Phase 3 |
| NCT05495620 | Dong-A University Hospital|Amgen |
Multiple Myeloma in Relapse|Multiple Myeloma, Refractory
|
August 1, 2022 | |
| NCT05090566 | Pfizer |
Multiple Myeloma
|
October 27, 2021 | Phase 2 |
| NCT00923663 | Medical University of Vienna |
MALT Lymphoma
|
July 2009 | Phase 2 |
| NCT01216683 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
December 13, 2010 | Phase 2 |
| NCT00602836 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2008 | Phase 2 |
| NCT02294357 | Oncotherapeutics|Amgen |
Multiple Myeloma
|
December 2014 | Phase 2 |
| NCT00536341 | SCRI Development Innovations, LLC|Celgene Corporation|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
January 2008 | Phase 1|Phase 2 |
| NCT02856438 | Bristol-Myers Squibb|AbbVie |
Multiple Myeloma
|
||
| NCT05328102 | Xencor, Inc. |
Diffuse Large-cell B-cell Lymphoma
|
June 30, 2022 | Phase 2 |
| NCT04722146 | Janssen Research & Development, LLC |
Multiple Myeloma
|
March 12, 2021 | Phase 1 |
| NCT02481934 | Joaquín Martínez López, MD, PhD|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario 12 de Octubre |
Multiple Myeloma
|
March 2013 | Phase 1 |
| NCT05288062 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma
|
March 22, 2022 | Phase 2 |
| NCT00695786 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage III Small Lymphocytic Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Ann Arbor Stage IV Small Lymphocytic Lymphoma
|
June 10, 2008 | Phase 2 |
| NCT04661007 | Incyte Biosciences Japan GK|Incyte Corporation |
Non Hodgkins Lymphoma|Diffuse Large B-cell Lymphoma
|
December 15, 2020 | Phase 1 |
| NCT02513186 | Sanofi |
Plasma Cell Myeloma
|
September 30, 2015 | Phase 1 |
| NCT00724568 | University of Michigan Rogel Cancer Center |
Multiple Myeloma
|
May 2008 | Phase 1|Phase 2 |
| NCT01374217 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Multiple Myeloma
|
April 2012 | Phase 2 |
| NCT05050097 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 22, 2021 | Phase 1 |
| NCT03863184 | Weill Medical College of Cornell University|AstraZeneca|Celgene Corporation |
Mantle Cell Lymphoma
|
October 11, 2019 | Phase 2 |
| NCT02215980 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
July 2014 | Phase 3 |
| NCT04970901 | ADC Therapeutics S.A. |
B-Cell Non-Hodgkin Lymphoma|Relapsed B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma
|
June 17, 2022 | Phase 1 |
| NCT00405756 | Celgene Corporation |
Newly Diagnosed Multiple Myeloma
|
January 2007 | Phase 3 |
| NCT01222195 | M.D. Anderson Cancer Center|Celgene Corporation |
Leukemia
|
February 2008 | Phase 2 |
| NCT00179686 | Celgene Corporation|Prologue Research International|Celgene |
Non-Small Cell Lung Cancer
|
March 2005 | Phase 2 |
| NCT01459211 | University College, London |
Chronic Lymphocytic Leukemia
|
May 2012 | Phase 2 |
| NCT00445692 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 10, 2007 | Phase 2 |
| NCT01352962 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Urethral Neoplasms|Neoplasms, Urethral|Cancer of the Urethra|Urethral Cancer
|
September 26, 2011 | Phase 1 |
| NCT04091126 | GlaxoSmithKline |
Multiple Myeloma
|
December 18, 2019 | Phase 1 |
| NCT02213913 | University of Chicago|National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia
|
July 29, 2014 | Phase 1|Phase 2 |
| NCT03011814 | City of Hope Medical Center|National Cancer Institute (NCI) |
Folliculotropic Mycosis Fungoides|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Sezary Syndrome|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
|
March 8, 2017 | Phase 1|Phase 2 |
| NCT02495922 | University of Heidelberg Medical Center |
Multiple Myeloma
|
June 2015 | Phase 3 |
| NCT04669171 | Enterome |
Follicular Lymphoma|Marginal Zone Lymphoma
|
July 5, 2021 | Phase 1|Phase 2 |
| NCT01755975 | Memorial Sloan Kettering Cancer Center|Saint Francis+Mount Sinai Regional Cancer Center|Weill Medical College of Cornell University|University of Nebraska|Celgene Corporation|Biologics, Inc. |
Multiple Myeloma|Non-Hodgkin´s Lymphoma
|
December 2012 | Phase 1|Phase 2 |
| NCT04129710 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ruijin Hospital|The First Affiliated Hospital of Nanchang University|Fujian Medical University Union Hospital|RenJi Hospital|Shanghai Tong Ren Hospital|Shandong Provincial Hospital|Cancer Hospital of Guangxi Medical University|Sir Run Run Shaw Hospital|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University|Ningbo Medical Center Lihuili Hospital|Yinzhou Hospital Affiliated to Medical School of Ningbo University|Zhejiang University |
Recurrent+RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
|
January 1, 2020 | Phase 2 |
| NCT00538733 | Weill Medical College of Cornell University|Celgene |
Multiple Myeloma
|
October 2007 | Phase 2 |
| NCT04032626 | St. Joseph´s Hospital and Medical Center, Phoenix|National Institute on Aging (NIA)|The Cleveland Clinic |
Cognitive Impairment, Mild|Cognitive Dysfunction|Amyloid Plaque|Neurodegeneration|Inflammation, Brain
|
July 22, 2020 | Phase 2 |
| NCT01562405 | Massachusetts General Hospital|Multiple Myeloma Research Consortium |
Multiple Myeloma
|
May 2012 | Phase 1 |
| NCT05497102 | Samsung Medical Center |
Multiple Myeloma
|
November 8, 2021 | Phase 2 |
| NCT01208662 | Paul G. Richardson, MD|Celgene Corporation|Millennium Pharmaceuticals, Inc.|Massachusetts General Hospital|Cape Cod Hospital|Beth Israel Deaconess Medical Center|Emory University|University of Michigan|Fox Chase Cancer Center|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Center|Barbara Ann Karmanos Cancer Institute|Duke University|University of California, San Francisco|University of Chicago|M.D. Anderson Cancer Center|UNC Lineberger Comprehensive Cancer Center|Roswell Park Cancer Institute|Stanford University|University of Mississippi Medical Center|Icahn School of Medicine at Mount Sinai|Wake Forest University Health Sciences|University of Arizona|OHSU Knight Cancer Institute|Eastern Maine Medical Center|University of California, San Diego|University of Alabama at Birmingham|University of Pittsburgh Medical Center|Ochsner Health System|University of Texas Southwestern Medical Center|State University of New York - Downstate Medical Center|Newton-Wellesley Hospital|Baylor College of Medicine|City of Hope Medical Center|University of Florida|Northwell Health|H. Lee Moffitt Cancer Center and Research Institute|Vanderbilt University Medical Center|Ohio State University|Huntsman Cancer Institute|Columbia University|Dana-Farber Cancer Institute |
Multiple Myeloma
|
October 2010 | Phase 3 |
| NCT01460420 | European Myeloma Network |
Hematologic Malignancies|Multiple Myeloma
|
November 2011 | Phase 1|Phase 2 |
| NCT00091624 | Celgene Corporation |
Multiple Myeloma
|
March 2003 | Phase 1 |
| NCT01838434 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation|Gilead Sciences|Biologics, Inc. |
Relapsed+Refractory Mantle Cell Lymphoma
|
July 2013 | Phase 1 |
| NCT04065789 | Tel-Aviv Sourasky Medical Center |
Myeloma Multiple|Myeloma, Plasma-Cell|Myeloma-Multiple|Plasma Cell Myeloma
|
May 2, 2018 | Phase 2 |
| NCT04231370 | Beijing Tongren Hospital |
NK+T Cell Lymphoma Nos
|
April 1, 2020 | Phase 2 |
| NCT04924647 | Peking Union Medical College Hospital |
Rosai-Dorfman Disease
|
June 8, 2021 | Phase 2 |
| NCT01668719 | Southwest Oncology Group|National Cancer Institute (NCI) |
DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma
|
November 2012 | Phase 1|Phase 2 |
| NCT00744536 | Sunnybrook Health Sciences Centre|Celgene |
Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Angiogenesis
|
January 2008 | Phase 2 |
| NCT00671801 | M.D. Anderson Cancer Center|Celgene |
Malignant Gliomas
|
April 29, 2008 | Phase 1 |
| NCT04876248 | Roswell Park Cancer Institute|GlaxoSmithKline |
Plasma Cell Myeloma
|
December 1, 2022 | Phase 2 |
| NCT04063189 | The First Hospital of Jilin University |
Multiple Myeloma in Relapse
|
March 21, 2017 | Phase 2 |
| NCT00096525 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Kidney Cancer
|
July 2004 | Phase 2 |
| NCT02159365 | Bristol-Myers Squibb |
Multiple Myeloma
|
March 8, 2014 | Phase 2 |
| NCT02368301 | Bristol-Myers Squibb |
Multiple Myeloma
|
||
| NCT01865110 | The Lymphoma Academic Research Organisation |
Mantle Cell Lymphoma
|
November 2013 | Phase 3 |
| NCT02906332 | Hackensack Meridian Health |
Multiple Myeloma
|
December 12, 2016 | Phase 2 |
| NCT02891811 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Amgen |
Multiple Myeloma
|
March 10, 2017 | Phase 2 |
| NCT01651039 | Ajai Chari|Novartis Pharmaceuticals|Icahn School of Medicine at Mount Sinai |
Multiple Myeloma
|
July 2012 | Phase 2 |
| NCT00607581 | IRCCS Policlinico S. Matteo|Celgene Corporation |
Amyloidosis
|
February 2008 | Phase 2 |
| NCT01559935 | Weill Medical College of Cornell University|Onyx Therapeutics, Inc. |
Multiple Myeloma
|
March 2012 | Phase 2 |
| NCT03100877 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Leukemia in Remission|Plasma Cell Myeloma
|
January 2018 | Phase 1|Phase 2 |
| NCT01029054 | University of Michigan Rogel Cancer Center|Onyx Therapeutics, Inc.|Celgene |
Multiple Myeloma
|
September 2009 | Phase 1|Phase 2 |
| NCT00632359 | M.D. Anderson Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
February 2008 | Phase 2 |
| NCT04436107 | BeiGene |
Relapsed+Refractory Diffuse Large B-Cell Lymphoma
|
September 11, 2020 | Phase 1 |
| NCT00179608 | Celgene|Prologue Research International |
Malignant Melanoma
|
September 1, 2005 | Phase 1 |
| NCT02370888 | University of Florida|Celgene Corporation |
Leukemia, Myeloid|Myelodysplastic Syndromes
|
May 16, 2016 | Phase 1 |
| NCT01351896 | National Cancer Institute (NCI) |
Ann Arbor Stage I Small Lymphocytic Lymphoma|Ann Arbor Stage II Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene|Small Lymphocytic Lymphoma|Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia
|
September 8, 2011 | Phase 2 |
| NCT01057121 | National Cancer Institute (NCI) |
AIDS-Related Kaposi Sarcoma|Recurrent Kaposi Sarcoma
|
August 27, 2010 | Phase 1|Phase 2 |
| NCT00829647 | Scripps Health|Bristol-Myers Squibb|Celgene Corporation |
Chronic Lymphocytic Leukemia|Leukemia
|
January 2009 | Phase 1|Phase 2 |
| NCT03376672 | Raija Silvennoinen|Nordic Myeloma Study Group|Celgene|Takeda|Helsinki University Central Hospital |
Multiple Myeloma
|
May 31, 2018 | Phase 2 |
| NCT03652064 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 6, 2018 | Phase 3 |
| NCT02628405 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma
|
May 20, 2016 | Phase 1|Phase 2 |
| NCT02728102 | National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Multiple Myeloma
|
July 2016 | Phase 2 |
| NCT01604031 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
B-cell Chronic Lymphocytic Leukemia
|
February 2013 | Phase 1 |
| NCT01029262 | Celgene |
Anemia
|
January 26, 2010 | Phase 3 |
| NCT01600053 | Thomas Kipps|Celgene Corporation|University of California, San Diego |
Chronic Lymphocytic Leukemia
|
November 2011 | Phase 2 |
| NCT01408199 | Hospital Universitari Vall d´Hebron Research Institute |
Cutaneous Lupus
|
January 2010 | Phase 4 |
| NCT00555100 | Celgene |
Multiple Myeloma
|
July 1, 2007 | Phase 1 |
| NCT00687674 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
August 2008 | Phase 1 |
| NCT01446133 | M.D. Anderson Cancer Center|Celgene Corporation |
Leukemia|Lymphoma
|
December 12, 2011 | Phase 2 |
| NCT05014100 | Puyang Oilfield General Hospital |
B-cell Lymphoma
|
September 1, 2021 | Phase 2 |
| NCT02272803 | Bristol-Myers Squibb|AbbVie |
Multiple Myeloma
|
February 20, 2015 | Phase 2 |
| NCT01358734 | Celgene |
Acute Myeloid Leukemia|Acute Myelogenous Leukemia
|
April 27, 2012 | Phase 2 |
| NCT01126450 | Case Comprehensive Cancer Center |
Colon Cancer|Rectal Cancer
|
October 2009 | Phase 1 |
| NCT05583617 | Hoffmann-La Roche |
Multiple Myeloma
|
November 30, 2022 | Phase 1|Phase 2 |
| NCT04140162 | University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
October 5, 2020 | Phase 2 |
| NCT00460031 | Case Comprehensive Cancer Center |
Prostate Cancer
|
September 1, 2006 | Phase 2 |
| NCT04782687 | US Oncology Research|Karyopharm Therapeutics Inc |
Multiple Myeloma|Myeloma Multiple|Kahler Disease|Myeloma, Plasma Cell|Myeloma-Multiple|Myelomatosis|Plasma Cell Myeloma
|
September 10, 2021 | Phase 2 |
| NCT00786851 | Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte |
MANTLE CELL LYMPHOMA
|
July 2008 | Phase 2 |
| NCT02203643 | Mario Boccadoro|University of Turin, Italy |
MULTIPLE MYELOMA (MM)
|
February 2015 | Phase 2 |
| NCT01155583 | Case Comprehensive Cancer Center |
Refractory Multiple Myeloma
|
June 2010 | Phase 1|Phase 2 |
| NCT01200004 | M.D. Anderson Cancer Center|Yukiguni Maitake Company Ltd. |
Advanced Cancers
|
April 2012 | Phase 1 |
| NCT03367143 | Ruijin Hospital |
Diffuse Large B-Cell Lymphoma Refractory
|
December 2016 | Phase 2 |
| NCT00619684 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
February 2008 | Phase 2 |
| NCT00352365 | National Cancer Institute (NCI) |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
June 2006 | Phase 2 |
| NCT00602459 | National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group |
Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
January 15, 2008 | Phase 2 |
| NCT03715296 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
October 18, 2018 | |
| NCT00179712 | Celgene Corporation|Prologue Research International |
Ovarian Cancer
|
April 2005 | Phase 1|Phase 2 |
| NCT00759603 | M.D. Anderson Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
September 2008 | Phase 2 |
| NCT04481815 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
PCNSL
|
October 1, 2020 | Phase 2 |
| NCT05222555 | MorphoSys AG |
Diffuse Large B Cell Lymphoma
|
July 19, 2022 | Phase 1|Phase 2 |
| NCT03110822 | Oncotherapeutics|Incyte Corporation |
Multiple Myeloma
|
February 1, 2017 | Phase 1 |
| NCT01127542 | The Christie NHS Foundation Trust|Celgene Corporation|Leukemia Research Fund |
Chronic Lymphocytic Leukaemia
|
May 2010 | Phase 2 |
| NCT00875667 | Celgene |
Mantle Cell Lymphoma|Lymphoma, Mantle-Cell
|
April 30, 2009 | Phase 2 |
| NCT00761449 | Nordic MDS Group |
MDS|AML
|
October 2007 | Phase 2 |
| NCT05438043 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 23, 2022 | Phase 3 |
| NCT01080391 | Amgen |
Relapsed Multiple Myeloma
|
July 14, 2010 | Phase 3 |
| NCT02155634 | Celgene |
Multiple Myeloma|Neoplasms|Plasma Cells|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases|Therapeutic Uses
|
July 2014 | Phase 3 |
| NCT03409432 | John Reneau|Ohio State University Comprehensive Cancer Center |
Lymphomatoid Papulosis|Primary Cutaneous Anaplastic Large Cell Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
|
March 16, 2018 | Phase 2 |
| NCT01145495 | National Cancer Institute (NCI) |
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma
|
June 15, 2010 | Phase 2 |
| NCT00051116 | Celgene Corporation|Celgene |
Multiple Myeloma
|
May 2002 | Phase 2 |
| NCT04490707 | Ge Zheng|Zhongda Hospital |
Acute Myeloid Leukemia in Remission
|
September 1, 2020 | Phase 3 |
| NCT04268498 | University of Miami|Amgen|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 11, 2020 | Phase 2 |
| NCT00603447 | Amgen |
Relapsed Multiple Myeloma
|
May 2008 | Phase 1 |
| NCT02232516 | Northwestern University|Celgene|National Cancer Institute (NCI) |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides+Sezary Syndrome|Stage IB Mycosis Fungoides+Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides+Sezary Syndrome|Stage IIB Mycosis Fungoides+Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIIA Mycosis Fungoides+Sezary Syndrome|Stage IIIB Mycosis Fungoides+Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IVA Mycosis Fungoides+Sezary Syndrome|Stage IVB Mycosis Fungoides+Sezary Syndrome
|
June 2015 | Phase 2 |
| NCT01615029 | Janssen Research & Development, LLC |
Multiple Myeloma
|
June 26, 2012 | Phase 1|Phase 2 |
| NCT02692339 | Celgene |
Multiple Myeloma
|
February 25, 2016 | |
| NCT02516696 | Weill Medical College of Cornell University|Celgene Corporation |
Multiple Myeloma
|
February 2016 | Phase 3 |
| NCT00480363 | PETHEMA Foundation|Celgene Corporation |
Multiple Myeloma
|
May 2007 | Phase 3 |
| NCT00698776 | Yale University|Kyowa Kirin Co., Ltd.|Celgene |
Myeloma
|
April 2009 | Phase 1 |
| NCT01440582 | M.D. Anderson Cancer Center|Novartis |
Myeloma
|
February 18, 2013 | Phase 1 |
| NCT01553786 | The Lymphoma Academic Research Organisation |
T-cell Lymphoma
|
November 2011 | Phase 2 |
| NCT00831766 | H. Lee Moffitt Cancer Center and Research Institute|Celgene |
Myelodysplastic Syndrome|Acute Myeloid Leukemia
|
June 25, 2009 | Phase 1|Phase 2 |
| NCT05575973 | Jianfeng Zhou|CSPC Ouyi Pharmaceutical Co., Ltd.|Huazhong University of Science and Technology |
Diffuse Large B-cell Lymphoma
|
October 10, 2022 | Phase 2 |
| NCT00477750 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
June 2005 | Phase 1|Phase 2 |
| NCT00179699 | Celgene Corporation|Prologue Research International|Celgene |
Non-Small Cell Lung Cancer
|
September 2005 | Phase 1 |
| NCT01034592 | Jason Robert Gotlib|Celgene Corporation|Stanford University |
Anemia|Leukemia|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)
|
November 2009 | Phase 1 |
| NCT01881789 | Amgen |
Multiple Myeloma
|
October 28, 2013 | Phase 1|Phase 2 |
| NCT05248633 | Peking Union Medical College Hospital |
Solitary Plasmacytoma
|
April 21, 2022 | Phase 2 |
| NCT05147493 | Hellenic Society of Hematology|Sanofi |
Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases
|
April 2022 | Phase 2 |
| NCT02160015 | National Cancer Institute (NCI) |
Ann Arbor Stage III Small Lymphocytic Lymphoma|Ann Arbor Stage IV Small Lymphocytic Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
May 9, 2014 | Phase 1 |
| NCT01246622 | Roswell Park Cancer Institute|Celgene Corporation |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia
|
February 7, 2011 | Phase 1 |
| NCT00352794 | M.D. Anderson Cancer Center|Celgene Corporation |
Myelofibrosis
|
July 7, 2006 | Phase 2 |
| NCT00100880 | National Cancer Institute (NCI) |
Childhood Atypical Teratoid+Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma
|
November 2004 | Phase 1 |
| NCT01246557 | Hospital Universitari Vall d´Hebron Research Institute |
Chronic Lymphatic Leukemia
|
December 2009 | Phase 1|Phase 2 |
| NCT04922567 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ruijin Hospital|Xinqiao Hospital of Chongqing|Union hospital of Fujian Medical University|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Southern Medical University, China|Shandong Provincial Hospital|Huashan Hospital|First Hospital of China Medical University|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Henan Provincial People´s Hospital|First Affiliated Hospital Xi´an Jiaotong University|Changhai Hospital|The Affiliated Hospital of Xuzhou Medical University|Wuhan Union Hospital, China|RenJi Hospital|Zhongda Hospital|The First Affiliated Hospital of Anhui Medical University|Hunan Cancer Hospital|First Affiliated Hospital of Harbin Medical University|Xiangya Hospital of Central South University|The First Affiliated Hospital of Dalian Medical University|Jilin Provincial Tumor Hospital|Shanxi Province Cancer Hospital|Zhongshan Hospital Xiamen University |
Peripheral T-Cell Lymphoma|Lenalidomide|CHOP
|
April 1, 2021 | Phase 2 |
| NCT02685826 | Celgene |
Multiple Myeloma
|
April 25, 2016 | Phase 1|Phase 2 |
| NCT02655458 | Hearn Jay Cho|Bristol-Myers Squibb|Icahn School of Medicine at Mount Sinai |
Multiple Myeloma
|
January 2016 | Phase 1 |
| NCT02983097 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH|Celgene|Amgen |
Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III�)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)
|
November 2010 | Phase 1|Phase 2 |
| NCT01076543 | National Cancer Institute (NCI) |
AIDS-Related Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Waldenstrom Macroglobulinemia
|
April 15, 2010 | Phase 1|Phase 2 |
| NCT04224493 | Epizyme, Inc. |
Relapsed+Refractory Follicular Lymphoma
|
December 19, 2019 | Phase 3 |
| NCT05137054 | Regeneron Pharmaceuticals |
Multiple Myeloma
|
August 17, 2022 | Phase 1 |
| NCT04301076 | National Cancer Institute (NCI) |
Acute Adult T-Cell Leukemia+Lymphoma|Adult T-Cell Leukemia+Lymphoma|Chronic Adult T-Cell Leukemia+Lymphoma|HTLV-1 Infection
|
June 15, 2020 | Phase 1 |
| NCT03212807 | Singapore General Hospital|National Cancer Center Singapore, Singapore|National University Hospital, Singapore|Raffles Hospital, Singapore |
EBV Related Non-Hodgkin´s Lymphoma|Primary CNS Lymphoma|Primary Testicular Lymphoma
|
August 2017 | Phase 2 |
| NCT00807599 | Memorial Sloan Kettering Cancer Center|Tufts Medical Center|Lahey Clinic |
Multiple Myeloma
|
December 10, 2008 | Phase 2 |
| NCT00839059 | University of Ulm |
Acute Myeloid Leukemia
|
January 2009 | Phase 1 |
| NCT05425654 | National Research Center for Hematology, Russia |
Primary CNS Lymphoma
|
May 17, 2021 | Phase 2 |
| NCT00675441 | M.D. Anderson Cancer Center|Celgene Corporation |
Graft-versus-Host Disease
|
April 2008 | Phase 2 |
| NCT02265510 | Incyte Corporation |
Solid Tumors|Advanced Malignancies|Metastatic Cancer
|
September 10, 2014 | Phase 1|Phase 2 |
| NCT05200312 | The First Affiliated Hospital with Nanjing Medical University |
Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma
|
February 1, 2022 | Phase 2 |
| NCT01947309 | Celgene |
Multiple Myeloma
|
November 2013 | |
| NCT00670358 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
August 25, 2008 | Phase 1|Phase 2 |
| NCT00114101 | National Cancer Institute (NCI) |
DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma
|
December 15, 2004 | Phase 3 |
| NCT01402284 | National Cancer Institute (NCI)|Celgene|Onyx Therapeutics, Inc.|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
July 21, 2011 | Phase 2 |
| NCT01133743 | University Health Network, Toronto|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
May 2010 | Phase 2 |
| NCT00165477 | Dana-Farber Cancer Institute|Celgene Corporation|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Massachusetts General Hospital|University of Virginia |
Glioblastoma|Gliosarcoma|Malignant Gliomas
|
September 2005 | Phase 2 |
| NCT00933426 | M.D. Anderson Cancer Center|Celgene Corporation |
Prostate Cancer
|
August 2009 | Phase 1 |
| NCT02921893 | Mayo Clinic|National Cancer Institute (NCI) |
Plasmacytoma|POEMS Syndrome
|
October 31, 2016 | Early Phase 1 |
| NCT00742560 | AbbVie (prior sponsor, Abbott)|Bristol-Myers Squibb|AbbVie |
Hematologic Cancer
|
August 2008 | Phase 2 |
| NCT00253344 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
June 2005 | Phase 1 |
| NCT01497496 | H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
January 26, 2012 | Phase 2 |
| NCT03012880 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
April 12, 2017 | Phase 2 |
| NCT00056160 | Celgene |
Multiple Myeloma
|
January 1, 2003 | Phase 3 |
| NCT03941860 | National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
June 1, 2021 | Phase 3 |
| NCT02225275 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma
|
March 31, 2016 | Phase 2 |
| NCT05351593 | James Rubenstein|Incyte Corporation|University of California, San Francisco |
CNS Lymphoma|Primary Central Nervous System Lymphoma|Secondary Central Nervous System Lymphoma
|
June 8, 2022 | Phase 1|Phase 2 |
| NCT00751296 | University Health Network, Toronto|Celgene |
Chronic Lymphocytic Leukaemia
|
August 2006 | Phase 2 |
| NCT05422027 | Xia Zhongjun|Antengene Corporation|Sun Yat-sen University |
Multiple Myeloma
|
July 25, 2022 | Phase 1|Phase 2 |
| NCT03477539 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
April 9, 2018 | Phase 2 |
| NCT04110301 | Beijing Mabworks Biotech Co., Ltd. |
Follicular Lymphoma and Marginal Zone Lymphoma
|
November 28, 2019 | Phase 1|Phase 2 |
| NCT00179621 | Celgene Corporation|ICON Clinical Research|Celgene |
Myelodysplastic Syndromes
|
July 2005 | Phase 3 |
| NCT01393756 | The Lymphoma Academic Research Organisation|Centre Henri Becquerel |
Follicular Lymphoma
|
December 2010 | Phase 2 |
| NCT05469893 | Irene Ghobrial, MD|Janssen Research & Development, LLC|Dana-Farber Cancer Institute |
High-risk Smoldering Multiple Myeloma|Smoldering Multiple Myeloma|Multiple Myeloma
|
August 10, 2022 | Phase 2 |
| NCT00735930 | National Cancer Institute (NCI) |
Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Thrombocytopenia
|
August 2008 | Phase 1 |
| NCT02529852 | M.D. Anderson Cancer Center|Celgene|Genentech, Inc. |
Lymphoma
|
November 4, 2015 | Phase 1|Phase 2 |
| NCT00403169 | The Cleveland Clinic|National Cancer Institute (NCI) |
Kidney Cancer
|
August 2004 | Phase 2 |
| NCT01582776 | The Lymphoma Academic Research Organisation |
Follicular Lymphoma Patients (Phase IB)|Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
|
October 3, 2012 | Phase 1|Phase 2 |
| NCT00903630 | Masonic Cancer Center, University of Minnesota|Celgene Corporation |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
April 2009 | Phase 1|Phase 2 |
| NCT00642954 | Merck Sharp & Dohme LLC |
Relapsed or Refractory Multiple Myeloma
|
February 13, 2008 | Phase 1 |
| NCT01116154 | City of Hope Medical Center |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-Cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia
|
May 2010 | Phase 1 |
| NCT04120350 | Peking Union Medical College Hospital|Beijing Tiantan Hospital|Xuanwu Hospital, Beijing|Peking University Third Hospital|Beijing Hospital|Peking University First Hospital|Chinese PLA General Hospital |
Primary Central Nervous System Lymphoma
|
August 16, 2019 | Phase 1|Phase 2 |
| NCT02075021 | NYU Langone Health|Celgene Corporation |
Relapsed or Refractory Multiple Myeloma
|
March 2014 | Phase 1|Phase 2 |
| NCT01698801 | Celgene |
Multiple Myeloma
|
October 1, 2012 | Phase 2 |
| NCT00478777 | Celgene Corporation|Celgene |
Relapsed or Refractory Multiple Myeloma
|
March 2007 | Phase 3 |
| NCT01530594 | King Faisal Specialist Hospital & Research Center |
Multiple Myeloma
|
January 2009 | Phase 3 |
| NCT01270932 | University Health Network, Toronto |
Renal Failure|Multiple Myeloma
|
November 2010 | Phase 2 |
| NCT04941937 | Juan Du|Shanghai Changzheng Hospital |
Multiple Myeloma
|
January 27, 2022 | Phase 2 |
| NCT02322320 | National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Multiple Myeloma
|
March 2015 | Phase 3 |
| NCT04635683 | Yazeed Sawalha|Ohio State University Comprehensive Cancer Center |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Nodal Marginal Zone Lymphoma|Recurrent Splenic Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Refractory Follicular Lymphoma|Refractory Grade 1 Follicular Lymphoma|Refractory Grade 2 Follicular Lymphoma|Refractory Grade 3a Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Nodal Marginal Zone Lymphoma|Refractory Splenic Marginal Zone Lymphoma|Refractory Waldenstrom Macroglobulinemia
|
September 30, 2022 | Phase 1 |
| NCT00843310 | NYU Langone Health|Celgene |
Multiple Myeloma
|
November 2008 | Phase 2 |
| NCT03269669 | National Cancer Institute (NCI) |
Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Follicular Lymphoma|Refractory Follicular Lymphoma
|
August 10, 2017 | Phase 2 |
| NCT02573896 | New Approaches to Neuroblastoma Therapy Consortium|Nationwide Children´s Hospital|United Therapeutics |
Neuroblastoma
|
January 14, 2019 | Phase 1 |
| NCT04934579 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Primary Central Nervous System Lymphoma
|
January 1, 2020 | Phase 2 |
| NCT03314636 | Oslo University Hospital|Nordic Myeloma Study Group |
Myeloma
|
March 16, 2018 | Phase 2 |
| NCT00885508 | Groupe Francophone des Myelodysplasies|Celgene Corporation |
Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia
|
February 2009 | Phase 2 |
| NCT03506802 | Jonsson Comprehensive Cancer Center|Novartis Pharmaceuticals |
HLA-A*0201 Positive Cells Present|NY-ESO-1 Positive Tumor Cells Present|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
July 10, 2018 | Phase 1 |
| NCT01208051 | National Cancer Institute (NCI) |
Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma
|
September 9, 2010 | Phase 1|Phase 2 |
| NCT04298372 | Seoul National University Hospital |
Amyloidosis Cardiac
|
February 20, 2019 | Phase 3 |
| NCT03959358 | University Health Network, Toronto |
Multiple Myeloma|Amyloidosis
|
July 3, 2020 | Phase 2 |
| NCT02419118 | Vejle Hospital |
Multiple Myeloma
|
January 2015 | Phase 2|Phase 3 |
| NCT03015896 | David Bond, MD|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center |
Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma
|
February 14, 2017 | Phase 1|Phase 2 |
| NCT01615042 | Mehrdad Abedi, MD|Celgene|University of California, Davis |
Acute Leukemia
|
August 2012 | Phase 1 |
| NCT04164368 | Fudan University |
Double Expressor Lymphoma
|
October 22, 2019 | Phase 2 |
| NCT01098656 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
July 2010 | Phase 3 |
| NCT02765854 | Emory University|Millennium Pharmaceuticals, Inc.|Multiple Myeloma Research Consortium |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
September 1, 2016 | Phase 2 |
| NCT04544059 | Nanfang Hospital of Southern Medical University |
Diffuse Large B Cell Lymphoma
|
October 1, 2020 | Phase 2 |
| NCT02348528 | Celgene |
Multiple Myeloma
|
September 11, 2012 | Phase 2 |
| NCT00784927 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
November 2008 | Phase 2 |
| NCT04604028 | National Taiwan University Hospital |
Antibiotics-unresponsive MALT Lymphoma|Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma|Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)
|
November 10, 2020 | Phase 2 |
| NCT04446962 | Institut Curie|National Cancer Institute, France |
Lymphoma, Large B-Cell, Diffuse|Central Nervous System Neoplasms, Primary
|
October 30, 2020 | Phase 1|Phase 2 |
| NCT01919619 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B-Cell Non-Hodgkin Lymphoma|Hematopoietic and Lymphoid Cell Neoplasm|Leukemia|Lymphoma|Plasma Cell Myeloma|T-Cell Non-Hodgkin Lymphoma
|
November 4, 2013 | Phase 2 |
| NCT01772420 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Adult Myelodysplastic Syndrome|Anemia|Chronic Myelomonocytic Leukemia
|
October 2012 | Phase 2 |
| NCT01359657 | Bristol-Myers Squibb |
Multiple Myeloma
|
September 2011 | Phase 1 |
| NCT05201248 | AbbVie|Genmab |
B-Cell Non-Hodgkin Lymphoma
|
March 10, 2022 | Phase 1 |
| NCT00065351 | Celgene |
Multiple Myeloma
|
July 1, 2003 | Phase 2 |
| NCT02253316 | Washington University School of Medicine|Millennium Pharmaceuticals, Inc.|Multiple Myeloma Research Consortium |
Multiple Myeloma
|
January 20, 2015 | Phase 2 |
| NCT01904643 | Stanford University|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia
|
February 2014 | Phase 1 |
| NCT01075321 | Mayo Clinic |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia
|
January 10, 2011 | Phase 1|Phase 2 |
| NCT04196491 | Celgene |
Multiple Myeloma
|
May 27, 2020 | Phase 1 |
| NCT00837031 | SCRI Development Innovations, LLC|Celgene Corporation |
Metastatic Pancreatic Cancer
|
February 2009 | Phase 2 |
| NCT04635189 | University of Rochester |
Multiple Myeloma
|
July 27, 2021 | Phase 2 |
| NCT03544281 | GlaxoSmithKline|Iqvia Pty Ltd |
Multiple Myeloma
|
September 20, 2018 | Phase 1|Phase 2 |
| NCT02446457 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma
|
July 31, 2015 | Phase 2 |
| NCT00142168 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Celgene Corporation|Genentech, Inc. |
Waldenstrom´s Macroglobulinemia
|
September 2004 | Phase 2 |
| NCT00699842 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Celgene Corporation|Thomas Jefferson University |
Myelodysplastic Syndrome|MDS|Low to Intermediate-1 MDS|Non-deletion 5q
|
July 2008 | Phase 1|Phase 2 |
| NCT00901615 | Lymphoma Study Association |
Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma
|
January 6, 2009 | Phase 1|Phase 2 |
| NCT01750762 | Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute |
Multiple Myeloma|Lymphoma
|
December 2012 | Phase 1 |
| NCT03729804 | University of Chicago |
Multiple Myeloma
|
May 7, 2019 | Phase 3 |
| NCT00546897 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
February 2007 | Phase 2 |
| NCT00098475 | National Cancer Institute (NCI) |
DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma
|
October 26, 2004 | Phase 3 |
| NCT00424047 | Celgene |
Multiple Myeloma
|
January 1, 2003 | Phase 3 |
| NCT01383928 | Millennium Pharmaceuticals, Inc.|Takeda |
Multiple Myeloma
|
October 31, 2011 | Phase 1|Phase 2 |
| NCT03004287 | University of Arkansas|Janssen, LP |
Multiple Myeloma
|
July 1, 2017 | Phase 2 |
| NCT04174196 | Memorial Sloan Kettering Cancer Center |
Plasmacytoma|Plasmacytoma of Bone|Multiple Myeloma
|
November 19, 2019 | Phase 2 |
| NCT01518465 | University of Southern California|National Cancer Institute (NCI)|Celgene Corporation |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
January 9, 2012 | Phase 2 |
| NCT02719613 | Bristol-Myers Squibb|AbbVie |
Multiple Myeloma
|
July 15, 2016 | Phase 2 |
| NCT01380106 | Boston VA Research Institute, Inc.|Celgene Corporation|Kansas City Veteran Affairs Medical Center|VA Pittsburgh Healthcare System|VA Greater Los Angeles Healthcare System|Michael E. DeBakey VA Medical Center|Edward Hines Jr. VA Hospital |
Multiple Myeloma
|
August 2010 | Phase 2 |
| NCT03500445 | University of Chicago|Janssen Scientific Affairs, LLC|Amgen |
Myeloma|Multiple Myeloma
|
February 13, 2019 | Phase 2 |
| NCT01522976 | National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia-1|Chronic Myelomonocytic Leukemia-2|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2
|
March 1, 2012 | Phase 2 |
| NCT04737889 | Henan Cancer Hospital |
Primary Central Nervous System Lymphoma
|
January 13, 2021 | Phase 2 |
| NCT04352205 | Emory University|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Renal Failure
|
May 7, 2020 | Phase 2 |
| NCT05488327 | Jiangxi Provincial People´s Hopital |
Dermatomyositis
|
August 1, 2022 | Not Applicable |
| NCT01463670 | Memorial Sloan Kettering Cancer Center|Montefiore Medical Center|State University of New York - Downstate Medical Center|University of Rochester|Weill Medical College of Cornell University|Stamford Hospital|Columbia University|State University of New York - Upstate Medical University |
Multiple Myeloma
|
October 28, 2011 | Phase 2 |
| NCT03948035 | Wuerzburg University Hospital|ClinAssess GmbH|Arbeitsgemeinschaft medikamentoese Tumortherapie |
Newly Diagnosed Multiple Myeloma
|
August 28, 2018 | Phase 3 |
| NCT00580242 | Massachusetts General Hospital|Celgene Corporation|Dana-Farber Cancer Institute |
Myelodysplasia
|
November 2007 | Phase 1 |
| NCT03523975 | University of Michigan Rogel Cancer Center |
Mantle Cell Lymphoma
|
December 24, 2018 | Phase 1 |
| NCT00968331 | University of Bologna |
Diffuse Large B-cell Lymphoma
|
March 2009 | Phase 2 |
| NCT05351346 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
June 1, 2022 | Phase 3 |
| NCT01421927 | University Hospital, Bordeaux |
Multiple Myeloma
|
August 2011 | Phase 1 |
| NCT02086604 | Washington University School of Medicine|Celgene|Seagen Inc. |
Lymphoma, Large B-Cell, Diffuse
|
September 18, 2014 | Phase 1 |
| NCT01647165 | National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
July 11, 2012 | Phase 2 |
| NCT00974233 | University of Wisconsin, Madison|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
October 2009 | Phase 2 |
| NCT00972842 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme LLC|Celgene Corporation |
Peripheral T-Cell Non-Hodgkin´s Lymphoma
|
September 2009 | Phase 1|Phase 2 |
| NCT02399085 | MorphoSys AG |
Diffuse Large B-cell Lymphoma
|
March 2016 | Phase 2 |
| NCT05371093 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Follicular Lymphoma
|
September 12, 2022 | Phase 3 |
| NCT01556035 | University Hospital, Bordeaux |
Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
|
July 2012 | Phase 2 |
| NCT01554852 | University of Leeds|Celgene|Merck Sharp & Dohme LLC|Amgen |
Multiple Myeloma
|
May 2010 | Phase 3 |
| NCT01342172 | Icahn School of Medicine at Mount Sinai|Celgene |
Urinary Bladder Neoplasms
|
March 2011 | Phase 1|Phase 2 |
| NCT01766583 | The Lymphoma Academic Research Organisation|Celgene Corporation |
Relapsed+Refractory B-cell Lymphoma
|
February 2013 | Phase 1 |
| NCT03495960 | International Extranodal Lymphoma Study Group (IELSG) |
Primary Central Nervous System Lymphoma
|
June 15, 2019 | Phase 2 |
| NCT00482261 | Peter MacCallum Cancer Centre, Australia|Celgene Corporation |
Multiple Myeloma
|
June 2007 | Phase 2 |
| NCT03746223 | Peking Union Medical College Hospital |
Primary Intraocular Lymphoma
|
November 15, 2018 | Phase 2 |
| NCT05032820 | Marcelo Pasquini, MD|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program|Celgene a wholly owned subsidiary of BMS|Medical College of Wisconsin |
Multiple Myeloma
|
January 5, 2022 | Phase 2 |
| NCT02077959 | Yvonne Efebera|CureTech Ltd|Ohio State University Comprehensive Cancer Center |
Multiple Myeloma
|
March 3, 2014 | Phase 1|Phase 2 |
| NCT04607772 | Karyopharm Therapeutics Inc |
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
November 18, 2020 | Phase 1|Phase 2 |
| NCT00908232 | Janssen-Cilag International NV |
Multiple Myeloma
|
May 2008 | Phase 2 |
| NCT03984097 | Takeda |
Multiple Myeloma
|
July 29, 2019 | Phase 1 |
| NCT02354313 | Fondazione Italiana Linfomi ONLUS |
MANTLE CELL LYMPHOMA
|
May 2010 | Phase 3 |
| NCT04049864 | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
Relapsed Neuroblastoma
|
January 9, 2019 | Early Phase 1 |
| NCT01412307 | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale|GiovanniPascale |
Recurrent Adult Hodgkin Lymphoma
|
July 2011 | Phase 1|Phase 2 |
| NCT01194791 | PETHEMA Foundation |
Primary Systemic Amyloidosis
|
October 2010 | Phase 2 |
| NCT01863550 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Plasma Cell Myeloma
|
December 2, 2013 | Phase 3 |
| NCT01349569 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene Corporation |
Multiple Myeloma
|
January 2012 | Phase 2 |
| NCT00996931 | Sutter Medical Foundation |
Autism
|
February 2009 | Phase 2 |
| NCT00238238 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
March 2006 | Phase 2 |
| NCT05498636 | The Affiliated Hospital of Qingdao University |
DLBCL
|
October 1, 2022 | Phase 1|Phase 2 |
| NCT03283046 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Multiple Myeloma
|
October 2017 | Phase 1 |
| NCT01779167 | Weill Medical College of Cornell University|Celgene Corporation |
Waldenstrom Macroglobulinemia
|
June 2012 | Phase 2 |
| NCT00502112 | Seagen Inc. |
Myelodysplastic Syndrome (MDS)
|
March 2008 | Phase 1 |
| NCT01375140 | M.D. Anderson Cancer Center|Incyte Corporation |
Myeloproliferative Diseases
|
September 22, 2011 | Phase 2 |
| NCT00644228 | National Cancer Institute (NCI) |
DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma
|
April 1, 2008 | Phase 3 |
| NCT02666209 | Dana-Farber Cancer Institute|Bristol-Myers Squibb |
Multiple Myeloma in Relapse|Multiple Myeloma
|
||
| NCT03669445 | University Hospital, Toulouse |
Multiple Myeloma
|
December 31, 2018 | Phase 2 |
| NCT00679367 | Boston Medical Center |
Multiple Myeloma
|
May 2008 | Phase 2 |
| NCT03993912 | University Hospital, Lille |
Multiple Myeloma
|
October 17, 2019 | Phase 3 |
| NCT02206503 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
March 2013 | Phase 2 |
| NCT03319667 | Sanofi |
Plasma Cell Myeloma
|
December 7, 2017 | Phase 3 |
| NCT01246076 | Washington University School of Medicine |
Myelodysplastic Syndromes
|
June 2011 | Phase 2 |
| NCT00977132 | Heinrich-Heine University, Duesseldorf |
Myelodysplastic Syndrome MDS
|
October 2009 | Phase 2 |
| NCT01629082 | National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) |
Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML)
|
June 6, 2012 | Phase 1 |
| NCT02406144 | PETHEMA Foundation|Celgene|Millennium Pharmaceuticals, Inc. |
Multiple Myeloma
|
November 2014 | Phase 3 |
| NCT04133636 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 7, 2019 | Phase 2 |
| NCT03647124 | Celgene |
Lymphoma, Mantle-Cell
|
March 13, 2019 | |
| NCT01282047 | French National Agency for Research on AIDS and Viral Hepatitis|Celgene Corporation|ANRS, Emerging Infectious Diseases |
HIV Infection Associated Kaposi Disease
|
October 2011 | Phase 2 |
| NCT04404088 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma
|
July 16, 2020 | Phase 2 |
| NCT05317416 | Pfizer |
Multiple Myeloma
|
March 25, 2022 | Phase 3 |
| NCT05211336 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)|Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
|
April 19, 2022 | Phase 1 |
| NCT00543114 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia
|
October 2007 | Phase 1 |
| NCT01830478 | Gruppo Italiano Studio Linfomi |
Indolent Non Hodgkin Lymphoma
|
April 2009 | Phase 2 |
| NCT03411031 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb |
Multiple Myeloma
|
October 4, 2018 | Phase 2 |
| NCT03815279 | Landspitali University Hospital|Amgen|Celgene|University of Iceland|Memorial Sloan Kettering Cancer Center |
Multiple Myeloma|Smoldering Multiple Myeloma
|
June 24, 2019 | Phase 2 |
| NCT01886859 | National Cancer Institute (NCI) |
Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma
|
April 26, 2013 | Phase 1 |
| NCT00864942 | Georgetown University|Celgene Corporation|Cephalon |
Chronic Lymphocytic Leukemia|Non-Hodgkin´s Lymphoma
|
February 2009 | Phase 1 |
| NCT00778752 | Universitätsklinikum Hamburg-Eppendorf |
Multiple Myeloma
|
April 2009 | Phase 1|Phase 2 |
| NCT01998971 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 18, 2014 | Phase 1 |
| NCT00153933 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|H. Lee Moffitt Cancer Center and Research Institute |
Refractory Multiple Myeloma|Relapsed Multiple Myeloma|Multiple Myeloma
|
August 2004 | Phase 1 |
| NCT02077166 | Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation |
Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
March 13, 2014 | Phase 1|Phase 2 |
| NCT01254617 | National Cancer Institute (NCI) |
Recurrent Colon Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Rectal Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Verrucous Carcinoma AJCC v7|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Cancer AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Verrucous Carcinoma AJCC v7|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Cancer AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Rectal Cancer AJCC v7|Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Verrucous Carcinoma AJCC v7|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVC Oral Cavity Cancer AJCC v6 and v7|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7|Tongue Carcinoma
|
February 10, 2011 | Phase 1 |
| NCT01575860 | Abramson Cancer Center of the University of Pennsylvania |
Lymphoma
|
April 2012 | Phase 1|Phase 2 |
| NCT05182957 | The First Affiliated Hospital of Soochow University |
Relapsed+Refractory Peripheral T-cell Lymphoma
|
December 14, 2021 | Phase 2 |
| NCT03720041 | University of Leeds|Cancer Research UK|Takeda|Celgene |
Multiple Myeloma
|
August 4, 2020 | Phase 3 |
| NCT01788189 | University Hospital, Essen|Celgene |
B-cell Lymphoma
|
January 2013 | Phase 1|Phase 2 |
| NCT03701711 | Ohio State University|Celgene Corporation|University of Michigan |
Demyelinating Sensorimotor Neuropathy
|
September 10, 2018 | Phase 1 |
| NCT05552937 | Beijing InnoCare Pharma Tech Co., Ltd. |
DLBCL
|
September 6, 2021 | Phase 2 |
| NCT00684242 | M.D. Anderson Cancer Center|Celgene Corporation |
Advanced Cancer|Pain
|
May 2008 | Phase 2 |
| NCT01122472 | The Lymphoma Academic Research Organisation |
Lymphoma|Diffuse Large B-cell Lymphoma
|
April 2009 | Phase 3 |
| NCT04824092 | MorphoSys AG |
Diffuse Large B-cell Lymphoma
|
May 11, 2021 | Phase 3 |
| NCT04052880 | Ajai Chari|Janssen, LP|Icahn School of Medicine at Mount Sinai |
Newly Diagnosed Multiple Myeloma
|
October 24, 2019 | Phase 2 |
| NCT01754857 | University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc. |
Lymphoid Leukemia|Small Lymphocytic Lymphoma|Lymphoma, Non-Hodgkin
|
November 12, 2013 | Phase 2 |
| NCT04040491 | Mingzhi Zhang|Zhengzhou University |
Peripheral T-cell Lymphoma
|
September 1, 2019 | Phase 4 |
| NCT01127386 | Florian Strasser, MD ABHPM|Celgene|Cantonal Hospital of St. Gallen |
Cancer Cachexia Syndrome
|
March 2009 | Phase 1|Phase 2 |
| NCT03673826 | Stichting Hemato-Oncologie voor Volwassenen Nederland |
Smouldering Myeloma
|
November 19, 2018 | Phase 2 |
| NCT02963610 | Fox Chase Cancer Center|Merck Sharp & Dohme LLC|Celgene |
Relapsed or Refractory Solid Tumors|Nonsmall Cell Lung Cancer
|
March 29, 2017 | Phase 1|Phase 2 |
| NCT02954406 | Millennium Pharmaceuticals, Inc.|Takeda |
Lymphoma, Non-Hodgkin
|
March 5, 2017 | Phase 1 |
| NCT04974216 | The Lymphoma Academic Research Organisation |
DLBCL
|
December 20, 2021 | Phase 2 |
| NCT01476787 | Celgene|The Lymphoma Academic Research Organisation |
Follicular Lymphoma
|
December 29, 2011 | Phase 3 |
| NCT00783367 | Abramson Cancer Center of the University of Pennsylvania |
Follicular Lymphoma|Marginal Zone B-Cell Lymphoma|MALT Lymphoma|Lymphoma of Mucosa-Associated Lymphoid Tissue|Lymphoma, Small Lymphocytic|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma
|
July 2008 | Phase 2 |
| NCT05025800 | M.D. Anderson Cancer Center |
Aggressive B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Composite Lymphoma|Indolent B-Cell Non-Hodgkin Lymphoma|Refractory Aggressive B-Cell Non-Hodgkin Lymphoma|Refractory Follicular Lymphoma|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma|Richter Syndrome
|
October 13, 2021 | Phase 1|Phase 2 |
| NCT01955499 | National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma
|
September 13, 2013 | Phase 1 |
| NCT03191981 | University of Leeds|Myeloma UK|Karyopharm Therapeutics Inc |
Myeloma Multiple
|
August 1, 2017 | Phase 1|Phase 2 |
| NCT01496976 | H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
March 30, 2012 | Phase 2 |
| NCT00064038 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma|Plasma Cell Neoplasm
|
November 2004 | Phase 3 |
| NCT03980171 | Peter MacCallum Cancer Centre, Australia |
Follicular Lymphoma
|
August 19, 2019 | Phase 1|Phase 2 |
| NCT02471820 | Meletios A. Dimopoulos|University of Athens |
Multiple Myeloma
|
November 2014 | Phase 2 |
| NCT04622579 | Guangdong Provincial People´s Hospital|Guangzhou First People´s Hospital|Foshan First People´s Hospital|Huizhou Municipal Central Hospital|Shantou Central Hospital |
Diffuse Large B Cell Lymphoma|Age Over 80 Years
|
October 23, 2020 | Phase 2 |
| NCT02018523 | Jun Zhang|Celgene Corporation|Baylor College of Medicine |
Carcinoma, Non-Small-Cell Lung
|
June 2014 | Phase 1 |
| NCT00621400 | Nantes University Hospital |
Amyloidosis
|
January 2008 | Phase 1|Phase 2 |
| NCT03232307 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CCND1 Positive|CD20-Positive Neoplastic Cells Present|Mantle Cell Lymphoma
|
July 1, 2019 | Phase 2 |
| NCT00120120 | Celgene Corporation|Celgene |
Radiculopathy
|
January 2005 | Phase 2|Phase 3 |
| NCT01856192 | National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
August 27, 2013 | Phase 2 |
| NCT01744912 | TG Therapeutics, Inc. |
Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B-cell Lymphomas|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Waldenstrom´s Macroglobulinemia
|
November 21, 2012 | Phase 1 |
| NCT04432402 | The First Affiliated Hospital with Nanjing Medical University |
Diffuse Large B Cell Lymphoma
|
June 14, 2020 | Not Applicable |
| NCT04578600 | Joseph Tuscano|National Cancer Institute (NCI)|Celgene|University of California, Davis |
Indolent B-Cell Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mucosa-Associated Lymphoid Tissue Lymphoma|Refractory Follicular Lymphoma|Refractory Hairy Cell Leukemia|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Small Lymphocytic Lymphoma
|
October 23, 2020 | Phase 1 |
| NCT00890552 | Stanford University|Celgene Corporation |
Leukemia|Amyloidosis
|
April 2009 | Not Applicable |
| NCT01125176 | Weill Medical College of Cornell University|Celgene |
Chronic Lymphocytic Leukemia
|
March 30, 2012 | Phase 2 |
| NCT04796857 | Huiqiang Huang|Sun Yat-sen University |
Non-GCB+ABC Diffuse Large B-Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma
|
March 31, 2021 | Phase 1|Phase 2 |
| NCT02041325 | Boston VA Research Institute, Inc.|Dana-Farber Cancer Institute |
Plasma Cell Disorder
|
April 2005 | Phase 2 |
| NCT04246086 | Hoffmann-La Roche |
Follicular Lymphoma
|
August 12, 2020 | Phase 1|Phase 2 |
| NCT01307605 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
February 9, 2011 | Phase 2 |
| NCT00322985 | AHS Cancer Control Alberta|Celgene Corporation|Alberta Cancer Foundation |
T-cell Lymphoma
|
June 2006 | Phase 2 |
| NCT01393964 | Bristol-Myers Squibb|AbbVie |
Multiple Myeloma
|
January 6, 2012 | Phase 1 |
| NCT01421186 | MorphoSys AG |
Multiple Myeloma
|
July 2011 | Phase 1|Phase 2 |
| NCT04609046 | National Cancer Institute (NCI) |
Central Nervous System Lymphoma|Diffuse Large B-Cell Lymphoma
|
January 15, 2021 | Phase 1 |
| NCT00482911 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Intraocular Melanoma|Malignant Conjunctival Neoplasm
|
April 2007 | Phase 2 |
| NCT02633137 | Memorial Sloan Kettering Cancer Center|Celgene Corporation |
Mantle Cell Lymphoma|Untreated
|
December 14, 2015 | Phase 2 |
| NCT01081431 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH|ClinAssess GmbH |
Myelodysplastic Syndromes
|
March 2010 | Phase 2 |
| NCT01729091 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Plasma Cell Leukemia|Plasma Cell Myeloma
|
June 10, 2013 | Phase 2 |
| NCT04404283 | Seagen Inc. |
Diffuse Large B-cell Lymphoma
|
August 20, 2020 | Phase 3 |
| NCT02631577 | Hoffmann-La Roche |
Lymphoma, Follicular
|
December 31, 2015 | Phase 1|Phase 2 |
| NCT01348503 | Indiana University School of Medicine|Celgene Corporation|Indiana University |
Hepatocellular Carcinoma
|
May 2011 | Phase 1 |
| NCT03373305 | City of Hope Medical Center |
CD30-Positive Neoplastic Cells Present|Folliculotropic Mycosis Fungoides|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome
|
March 2019 | Phase 1 |
| NCT00737529 | Celgene |
Mantle Cell Lymphoma
|
December 22, 2008 | Phase 2 |
| NCT02575144 | PETHEMA Foundation|Cabyc, S.L. |
Multiple Myeloma
|
September 2015 | Phase 3 |
| NCT01003769 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Chronic Lymphocytic Leukemia
|
July 9, 2015 | Phase 1|Phase 2 |
| NCT00398515 | National Cancer Institute (NCI) |
Refractory Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
March 2007 | Phase 1 |
| NCT03376477 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Celgene|Aduro Biotech, Inc. |
Multiple Myeloma
|
September 23, 2019 | Phase 2 |
| NCT01619761 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
May 3, 2013 | Phase 1 |
| NCT05552222 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 25, 2022 | Phase 3 |
| NCT00413036 | Celgene |
Lymphoma, Non-Hodgkin´s
|
June 2006 | Phase 2 |
| NCT02371577 | University of California, San Diego|Celgene Corporation |
Chronic Lymphocytic Leukemia (CLL)
|
February 1, 2017 | Phase 2 |
| NCT00655668 | Celgene |
T-cell Non-Hodgkin´s Lymphoma
|
March 1, 2008 | Phase 2 |
| NCT01198054 | PETHEMA Foundation |
AML
|
January 2011 | Phase 4 |
| NCT01132586 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Alkylating Agent-Related Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia
|
May 2010 | Phase 1 |
| NCT02619682 | Fred Hutchinson Cancer Center |
Plasma Cell Myeloma|Transplant-Related Carcinoma
|
December 30, 2015 | Phase 2 |
| NCT02897830 | University Hospital, Toulouse|Takeda|Celgene |
Multiple Myeloma
|
August 5, 2016 | Phase 2 |
| NCT03785184 | AbbVie|Genentech, Inc.|Celgene Corporation |
Multiple Myeloma
|
April 29, 2019 | Phase 2 |
| NCT02568553 | National Cancer Institute (NCI) |
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Grade 3b Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mediastinal Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Grade 1 Follicular Lymphoma|Refractory Grade 2 Follicular Lymphoma|Refractory Grade 3 Follicular Lymphoma|Refractory Grade 3a Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Mediastinal Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma
|
June 14, 2016 | Phase 1 |
| NCT01673308 | Ulsan University Hospital|Cooperative Study Group A for Hematology |
Myelodysplastic Syndrome
|
August 2012 | Phase 2 |
| NCT02918331 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
September 2016 | Phase 1 |
| NCT02898259 | Brian Hill|The Cleveland Clinic|Case Comprehensive Cancer Center |
B Cell Lymphoma|Lymphoma
|
February 20, 2017 | Phase 1|Phase 2 |
| NCT05280275 | Hellenic Society of Hematology|GlaxoSmithKline |
Multiple Myeloma|Neoplasms|Neoplasms, Plasma Cell|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease
|
March 15, 2022 | Phase 1|Phase 2 |
| NCT01415752 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma|Neurotoxicity|Therapy-related Toxicity
|
May 22, 2012 | Phase 2 |
| NCT01045928 | Case Comprehensive Cancer Center |
Adult Non-Hodgkin Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia
|
January 2010 | Phase 1 |
| NCT04329130 | Sun Yat-sen University |
Relapsed or Refractory Peripheral T-cell Lymphoma
|
March 27, 2020 | Phase 2 |
| NCT01180569 | Memorial Sloan Kettering Cancer Center|Celgene Corporation |
Lymphoma|Follicular Lymphoma
|
August 2010 | Phase 1|Phase 2 |
| NCT03617731 | University of Heidelberg Medical Center |
Multiple Myeloma
|
October 18, 2018 | Phase 3 |
| NCT05429268 | Incyte Corporation |
Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma
|
November 16, 2022 | Phase 3 |
| NCT02986451 | Sun Yat-sen University|China Food and Drug Administration |
Relapse+Refractory Multiple Myeloma
|
December 2016 | Phase 2 |
| NCT01054144 | H. Lee Moffitt Cancer Center and Research Institute|Celgene |
Multiple Myeloma
|
January 14, 2010 | Phase 2 |
| NCT01481194 | Vejle Hospital|The University of Hong Kong |
Multiple Myeloma
|
November 2011 | Phase 2 |
| NCT01712828 | Celgene|Covance |
Healthy
|
October 1, 2012 | Phase 1 |
| NCT02036502 | Merck Sharp & Dohme LLC |
Multiple Myeloma
|
February 14, 2014 | Phase 1 |
| NCT03710603 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 14, 2018 | Phase 3 |
| NCT02917941 | Takeda |
Relapsed and+or Refractory Multiple Myeloma
|
November 1, 2016 | Phase 2 |
| NCT03837873 | Institute of Hematology & Blood Diseases Hospital |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Transformed Lymphoma
|
January 21, 2019 | Phase 2 |
| NCT00466921 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
April 19, 2005 | Phase 2 |
| NCT00717756 | Brown University|Memorial Hospital of Rhode Island|Roger Williams Medical Center |
Liver Cancer
|
January 2009 | Phase 2 |
| NCT02335983 | Amgen |
Multiple Myeloma
|
April 30, 2015 | Phase 1 |
| NCT04272775 | Takeda |
Relapsed and+or Refractory Multiple Myeloma
|
June 5, 2012 | Phase 1 |
| NCT01611259 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
|
May 2012 | Phase 2 |
| NCT00294632 | M.D. Anderson Cancer Center|Celgene Corporation |
Lymphoma
|
February 2006 | Phase 1|Phase 2 |
| NCT01995669 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Grade 3a Follicular Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma
|
May 21, 2014 | Phase 1|Phase 2 |
| NCT00179660 | Celgene Corporation|Prologue Research International|Celgene |
Non-Hodgkins Lymphoma
|
August 2005 | Phase 2 |
| NCT03903406 | Multinational Center for Quality of Life Research, Russia |
Relapsed and+or Refractory Multiple Myeloma
|
May 2019 | |
| NCT03809780 | Kosin University Gospel Hospital|Celgene |
Multiple Myeloma
|
March 11, 2019 | Phase 2 |
| NCT01433965 | University of California, Davis|Celgene |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
August 8, 2012 | Phase 1 |
| NCT03106324 | Celgene |
Multiple Myeloma
|
March 31, 2017 | |
| NCT02525250 | Institut Paoli-Calmettes |
Acute Myeloid Leukemia or Myelodysplasic Syndrome
|
December 2012 | Not Applicable |
| NCT01965353 | Dana-Farber Cancer Institute|Novartis |
Multiple Myeloma in Relapse
|
October 2013 | Phase 1 |
| NCT03952091 | I-Mab Biopharma Co. Ltd. |
Multiple Myeloma in Relapse|Refractory Multiple Myeloma
|
March 27, 2019 | Phase 3 |
| NCT04539236 | Mikkael Sekeres, MD|Celgene|Bristol-Myers Squibb|University of Miami |
Myelodysplastic Syndromes
|
November 9, 2021 | Phase 1|Phase 2 |
| NCT00799513 | IRCCS San Raffaele|Celgene Corporation |
Diffuse Large B-cell Lymphoma
|
October 2009 | Phase 2 |
| NCT00522392 | National Cancer Institute (NCI) |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
September 2007 | Phase 3 |
| NCT00928486 | Celgene |
Multiple Myeloma
|
April 28, 2009 | Phase 3 |
| NCT01132989 | Florida Academic Dermatology Centers|Celgene Corporation |
Cutaneous T Cell Lymphoma
|
May 2010 | Phase 2 |
| NCT01924169 | M.D. Anderson Cancer Center|Celgene Corporation |
Hematologic Disorder
|
November 24, 2014 | Phase 2 |
| NCT05497804 | Mayo Clinic|National Cancer Institute (NCI) |
ISS Stage III Plasma Cell Myeloma|Plasma Cell Myeloma
|
September 22, 2022 | Phase 2 |
| NCT00915408 | King´s College Hospital NHS Trust |
Multiple Myeloma
|
September 2006 | Phase 1|Phase 2 |
| NCT00720850 | Technische Universität Dresden|Celgene Corporation |
Myelodysplastic Syndromes|Acute Myelogenous Leukemia
|
April 2008 | Phase 2 |
| NCT05623020 | Pfizer |
Multiple Myeloma
|
November 15, 2022 | Phase 3 |
| NCT04257448 | GWT-TUD GmbH|Celgene|AstraZeneca |
Pancreas Cancer|Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma
|
May 25, 2020 | Phase 1|Phase 2 |
| NCT01155505 | Southern Europe New Drug Organization|Celgene Corporation |
Advanced Solid Tumors
|
November 2009 | Phase 1 |
| NCT00415064 | AEterna Zentaris |
Multiple Myeloma
|
December 2006 | Phase 1 |
| NCT01379274 | Rush University Medical Center|Celgene Corporation |
MDS
|
January 2011 | Phase 2 |
| NCT01016600 | Washington University School of Medicine|Celgene Corporation |
Leukemia, Myeloid, Acute
|
April 2010 | Phase 1|Phase 2 |
| NCT01032291 | Celgene Corporation|Celgene |
Colorectal Cancer
|
December 2009 | Phase 2 |
| NCT00104962 | National Cancer Institute (NCI) |
Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ringed Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Secondary Myelodysplastic Syndromes|Unspecified Childhood Solid Tumor, Protocol Specific
|
March 2005 | Phase 1 |
| NCT00525447 | Seagen Inc.|Genentech, Inc. |
Multiple Myeloma
|
August 2007 | Phase 1 |
| NCT04751877 | Poitiers University Hospital|Intergroupe Francophone du Myelome|Sanofi |
Multiple Myeloma|Myeloma
|
July 17, 2021 | Phase 3 |
| NCT01702831 | University Health Network, Toronto|Princess Margaret Hospital, Canada|Otsuka Pharmaceutical Development & Commercialization, Inc.|Celgene Corporation |
Multiple Myeloma
|
October 1, 2013 | Phase 2 |
| NCT01166035 | Medical University Innsbruck|Celgene Corporation|Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO) |
Solid Tumors
|
March 2010 | Phase 1|Phase 2 |
| NCT00874978 | King´s College Hospital NHS Trust |
Myelodysplastic Syndromes
|
January 2005 | Phase 2 |
| NCT01217203 | Innate Pharma |
Patients With Multiple Myeloma Experiencing a|First or Second Relapse
|
September 2010 | Phase 1 |
| NCT00899431 | M.D. Anderson Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
May 6, 2009 | Phase 2 |
| NCT02871219 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage II Grade 1 Follicular Lymphoma|Ann Arbor Stage II Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Bulky Disease|Fatigue|Fever|Grade 3a Follicular Lymphoma|Night Sweats|Splenomegaly|Weight Loss
|
December 6, 2016 | Phase 2 |
| NCT01215344 | Vanderbilt-Ingram Cancer Center |
Multiple Myeloma
|
November 2010 | Phase 2 |
| NCT01827137 | Sellas Life Sciences Group |
Multiple Myeloma|Minimal Residual Disease|High-Risk Cancer
|
April 2013 | Not Applicable |
| NCT04038411 | Mingzhi Zhang|Zhengzhou University |
NK+T Cell Lymphoma
|
April 1, 2019 | Phase 4 |
| NCT03934684 | Amgen |
Relapsed Refractory Multiple Myeloma
|
September 16, 2019 | Phase 4 |
| NCT04134936 | MorphoSys AG |
Diffuse Large B-cell Lymphoma
|
December 11, 2019 | Phase 1 |
| NCT01556776 | German CLL Study Group|Celgene |
Chronic Lymphocytic Leukemia
|
July 20, 2012 | Phase 3 |
| NCT01401322 | Stanford University|Celgene Corporation |
Leukemia|Relapsed Adult Acute Lymphocytic Leukemia
|
January 2011 | Phase 2 |
| NCT01472562 | Weill Medical College of Cornell University|Celgene |
Mantle Cell Lymphoma
|
July 29, 2011 | Phase 2 |
| NCT02521714 | Celgene |
Healthy Volunteers
|
August 14, 2015 | Phase 1 |
| NCT00466895 | Leslie Andritsos|Celgene Corporation|Ohio State University Comprehensive Cancer Center |
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia
|
April 2007 | Phase 1 |
| NCT01542918 | James Rubenstein|Celgene|Genentech, Inc.|University of California, San Francisco |
Recurrent+Refractory CNS|Intraocular Lymphoma
|
December 17, 2012 | Phase 1 |
| NCT01183663 | M.D. Anderson Cancer Center|Celgene |
Advanced Cancers
|
August 2010 | Phase 1 |
| NCT01531998 | M.D. Anderson Cancer Center|Janssen Services, LLC |
Myeloma
|
May 2012 | Phase 1|Phase 2 |
| NCT01239797 | Bristol-Myers Squibb|AbbVie |
Lymphoma|Multiple Myeloma
|
June 20, 2011 | Phase 3 |
| NCT05392257 | Qingdao Central Hospital |
Overall Survival
|
May 1, 2022 | Phase 2 |
| NCT01996865 | Celgene |
Lymphoma, Non-Hodgkin
|
April 1, 2014 | Phase 3 |
| NCT02371590 | University of California, San Diego|Celgene Corporation|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
February 2018 | Phase 2 |
| NCT01704781 | Bionor Immuno AS|Celgene Corporation |
HIV-1 Infection
|
September 2012 | Phase 1|Phase 2 |
| NCT01264315 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
September 2008 | Phase 2 |
| NCT01121757 | Duke University|Celgene |
Follicular Lymphoma|Marginal Zone Lymphoma
|
April 2010 | Phase 2 |
| NCT04447027 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Cutaneous T-Cell Lymphoma|Mature T-cell Malignancies|Peripheral T-Cell Lymphoma|Relapsed+ Refractory T-cell Malignancies
|
December 17, 2020 | Phase 1 |
| NCT01055301 | Southwest Oncology Group|National Cancer Institute (NCI) |
Multiple Myeloma|Plasma Cell Myeloma
|
July 2011 | Phase 2 |
| NCT01706666 | Mayo Clinic |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
December 7, 2012 | Phase 2 |
| NCT03829371 | University of Turin, Italy |
Multiple Myeloma
|
January 3, 2019 | Phase 4 |
| NCT02126553 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Alkylating Agent-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
November 13, 2014 | Phase 2 |
| NCT04447716 | Thomas Jefferson University|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Follicular Lymphoma|Refractory Indolent Adult Non-Hodgkin Lymphoma|Refractory Marginal Zone Lymphoma
|
October 16, 2020 | Phase 1 |
| NCT05058755 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Natural Killer+T-Cell Lymphoma, Nasal and Nasal-Type
|
September 17, 2021 | Not Applicable |
| NCT02279654 | Celgene |
Myelodysplastic Syndrome
|
December 17, 2014 | |
| NCT04712097 | Hoffmann-La Roche |
Relapsed or Refractory Follicular Lymphoma
|
October 27, 2021 | Phase 3 |
| NCT01593410 | Celgene |
Multiple Myeloma
|
August 1, 2010 | Phase 2 |
| NCT01617213 | University of Virginia |
Multiple Myeloma
|
April 2012 | Phase 2 |
| NCT00446433 | Celgene Corporation |
Crohn´s Disease
|
March 2002 | Phase 2 |
| NCT04326296 | LiNing|Henan Cancer Hospital |
Colorectal Neoplasms
|
May 30, 2020 | Phase 1 |
| NCT01342692 | Assistance Publique - Hôpitaux de Paris |
MDS
|
June 2011 | Phase 2 |
| NCT02086552 | Mayo Clinic|National Cancer Institute (NCI)|Novartis Pharmaceuticals |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 17, 2014 | Phase 2 |
| NCT01053806 | Tel-Aviv Sourasky Medical Center |
Myelodysplastic Syndrome
|
August 2011 | Phase 2 |
| NCT00093028 | University of Arkansas |
Multiple Myeloma
|
January 2004 | Phase 3 |
| NCT00567229 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
November 2007 | Phase 2 |
| NCT01197560 | Celgene |
Diffuse Large B-cell Lymphoma
|
September 2, 2010 | Phase 2|Phase 3 |
| NCT00622336 | Celgene |
Multiple Myeloma
|
April 1, 2003 | Phase 3 |
| NCT00067743 | Celgene Corporation|Celgene |
Complex Regional Pain Syndrome (RSD)
|
August 2003 | Phase 2 |
| NCT04071457 | Southwest Oncology Group|National Cancer Institute (NCI)|Janssen, LP|Adaptive |
Multiple Myeloma
|
June 27, 2019 | Phase 3 |
| NCT00439231 | Georg Aue, M.D.|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma
|
February 2007 | Phase 2 |
| NCT01274533 | Columbia University|Celgene Corporation |
Adult T Cell Leukemia+Lymphoma
|
December 2010 | Phase 2 |
| NCT00434239 | Peter MacCallum Cancer Centre, Australia|Celgene Corporation |
Myelodysplasia
|
February 2007 | Early Phase 1 |
| NCT02544308 | University College, London|Cancer Research UK|Celgene |
Plasmacytoma
|
March 10, 2017 | Phase 3 |
| NCT03333746 | Yvonne Efebera|National Cancer Institute (NCI)|American Cancer Society, Inc.|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
March 21, 2018 | Phase 2 |
| NCT00166413 | Mayo Clinic |
Amyloidosis
|
April 2005 | Phase 2 |
| NCT01985477 | M.D. Anderson Cancer Center|Celgene Corporation |
Myeloma
|
December 2013 | Phase 1 |
| NCT02928419 | Associazione Qol-one |
Myelodysplastic Syndromes
|
May 2015 | Phase 2 |
| NCT02721043 | Nina Bhardwaj|Icahn School of Medicine at Mount Sinai |
Solid Tumors
|
April 2016 | Phase 1 |
| NCT01035463 | University of Nebraska|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Negative|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma
|
November 12, 2009 | Phase 1|Phase 2 |
| NCT05583071 | University of Cologne|Incyte Corporation |
Non-Hodgkin Lymphoma
|
January 2023 | Phase 2 |
| NCT02334865 | Roswell Park Cancer Institute|Celgene |
Partial Response of Multiple Myeloma or Plasma Cell Leukemia|Plasma Cell Myeloma
|
April 13, 2017 | Phase 1 |
| NCT05243797 | European Myeloma Network|Janssen Pharmaceutica |
Multiple Myeloma
|
April 12, 2022 | Phase 3 |
| NCT03223610 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma
|
February 9, 2018 | Phase 1|Phase 2 |
| NCT01649791 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene Corporation |
B-cell Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia
|
January 2010 | Not Applicable |
| NCT01109004 | National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) |
Multiple Myeloma
|
May 2010 | Phase 3 |
| NCT00044382 | Celgene |
Myelodysplastic Syndrome
|
February 1, 2002 | Phase 2 |
| NCT02532257 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage II Follicular Lymphoma|Ann Arbor Stage II Marginal Zone Lymphoma|Ann Arbor Stage III Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|CD20 Positive|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma
|
April 11, 2016 | Phase 2 |
| NCT05564052 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma, Mantle-Cell
|
December 21, 2022 | Phase 2|Phase 3 |
| NCT00179751 | Celgene Corporation|Prologue Research International|Celgene |
Pancreatic Cancer
|
April 2005 | Phase 1|Phase 2 |
| NCT04542824 | Genmab|AbbVie |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma
|
August 20, 2020 | Phase 1|Phase 2 |
| NCT01335399 | Bristol-Myers Squibb|AbbVie |
Multiple Myeloma
|
August 4, 2011 | Phase 3 |
| NCT01088373 | Groupe Francophone des Myelodysplasies|Celgene |
Myelodysplastic Syndromes
|
March 25, 2010 | Phase 2 |
| NCT01429025 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation |
Refractory+Relapsed Indolent Non-Hodgkin Lymphoma
|
May 2012 | Phase 1 |
| NCT02579863 | Merck Sharp & Dohme LLC |
Multiple Myeloma
|
October 19, 2015 | Phase 3 |
| NCT01732861 | Celgene |
Leukemia Lymphocytic Chronic B-Cell
|
December 28, 2012 | Phase 1 |
| NCT01093196 | Fondazione EMN Italy Onlus |
Multiple Myeloma
|
October 2009 | Phase 3 |
| NCT01217957 | Millennium Pharmaceuticals, Inc.|Takeda |
Multiple Myeloma
|
November 22, 2010 | Phase 1|Phase 2 |
| NCT01782963 | Massachusetts General Hospital |
Multiple Myeloma
|
March 2013 | Phase 2 |
| NCT01956695 | Institut Curie|Centre Hospitalier Universitaire, Amiens|Institut Bergonié|University Hospital, Clermont-Ferrand|University Hospital, Lille|Central Hospital, Nancy, France|Groupe Hospitalier Pitie-Salpetriere|Centre Henri Becquerel|University Hospital, Tours|Centre Leon Berard|University Hospital, Grenoble |
Lymphoma|Relapse
|
September 18, 2013 | Phase 2 |
| NCT00848328 | University of California, Davis|Celgene |
Lymphoma
|
August 25, 2008 | Phase 2 |
| NCT05573802 | Hellenic Society of Hematology|GlaxoSmithKline |
Multiple Myeloma|Neoplasms|Neoplasm, Plasma Cell|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease
|
October 24, 2022 | Phase 1|Phase 2 |
| NCT04891809 | Arbeitsgemeinschaft medikamentoese Tumortherapie|University of Navarra|Medical University of Vienna|Assign Data Management and Biostatistics GmbH|WiSP GmbH|Sanofi |
Newly Diagnosed Multiple Myeloma
|
October 20, 2021 | Phase 2 |
| NCT05123131 | Cancer Trials Ireland|Sanofi|Dana-Farber Cancer Institute |
Multiple Myeloma
|
April 1, 2022 | Phase 2 |
| NCT05145400 | UNC Lineberger Comprehensive Cancer Center|Genzyme, a Sanofi Company |
Multiple Myeloma|Cancer
|
February 18, 2022 | Phase 2 |
| NCT01011894 | Memorial Sloan Kettering Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia|Leukemia
|
November 6, 2009 | Phase 2 |
| NCT00540644 | Attaya Suvannasankha|Celgene|Indiana University |
Multiple Myeloma
|
October 2007 | Phase 2 |
| NCT00551928 | Fondazione EMN Italy Onlus |
Multiple Myeloma|Newly Diagnosed Patients
|
June 2007 | Phase 3 |
| NCT03730740 | Samsung Medical Center |
Relapsed and+or Refractory Non-Hodgkin T-cell Lymphoma
|
November 16, 2018 | Phase 2 |
| NCT00867308 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Myelodysplastic Syndrome
|
July 2009 | Phase 2 |
| NCT02538965 | Celgene |
Leukemia, Myeloid
|
November 19, 2015 | Phase 2 |
| NCT00112827 | City of Hope Medical Center |
Refractory Multiple Myeloma|Smoldering Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
November 2004 | Phase 1|Phase 2 |
| NCT04978584 | M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma
|
March 3, 2022 | Phase 2 |
| NCT00287287 | Kenneth Ain|Celgene Corporation|University of Kentucky |
Thyroid Neoplasms
|
February 2006 | Phase 2 |
| NCT01218555 | Emory University|Celgene|Novartis |
Solid Organ Malignancies|Adenoidcystic Carcinoma|Neuroendocrine Tumors
|
September 9, 2010 | Phase 1 |
| NCT01378091 | Columbia University|Celgene Corporation |
Prostate Cancer
|
August 2005 | Phase 1 |
| NCT02969837 | University of Chicago|Bristol-Myers Squibb|Amgen|Multiple Myeloma Research Foundation |
Multiple Myeloma
|
July 10, 2017 | Phase 2 |
| NCT03949062 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
March 13, 2019 | Phase 2 |
| NCT00420849 | Celgene Corporation|Celgene |
Multiple Myeloma
|
November 2006 | Phase 3 |
| NCT00939510 | Robert Dreicer MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center |
Prostate Cancer
|
July 2005 | Phase 1|Phase 2 |
| NCT04818372 | Keymed Biosciences Co.Ltd |
Multiple Myeloma|Lymphoma
|
April 26, 2021 | Phase 1 |
| NCT00087672 | M.D. Anderson Cancer Center|Celgene Corporation |
Myelofibrosis
|
July 2004 | Phase 2 |
| NCT02937571 | Memorial Sloan Kettering Cancer Center|Onyx+Amgen|Celgene |
Multiple Myeloma
|
October 2016 | Phase 1|Phase 2 |
| NCT01133665 | University of Chicago|Celgene Corporation |
Squamous Cell Carcinoma
|
February 2010 | Phase 2 |
| NCT00602641 | National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
February 29, 2008 | Phase 3 |
| NCT00267059 | M.D. Anderson Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia|Leukemia
|
December 2005 | Phase 2 |
| NCT00179725 | Celgene Corporation|Prologue Research International|Celgene |
Ovarian Cancer
|
November 2005 | Phase 1|Phase 2 |
| NCT05076097 | Tianjin Medical University Cancer Institute and Hospital |
Mantle Cell Lymphoma
|
September 30, 2021 | Phase 2 |
| NCT03937635 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Smoldering Plasma Cell Myeloma
|
April 30, 2019 | Phase 3 |
| NCT02389517 | University of Chicago|National Cancer Institute (NCI)|Multiple Myeloma Research Foundation |
Plasma Cell Myeloma|Residual Disease
|
March 2, 2015 | Phase 2 |
| NCT05572229 | University Hospital, Lille |
Multiple Myeloma
|
February 2023 | Phase 2 |
| NCT00540007 | Washington University School of Medicine|Celgene Corporation |
Hodgkin Disease
|
September 6, 2007 | Phase 2 |
| NCT01794039 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
March 2014 | Phase 2 |
| NCT03703167 | Memorial Sloan Kettering Cancer Center|Pharmacyclics LLC. |
Primary Central Nervous System Lymphoma (PCNSL)|Secondary Central Nervous System Lymphoma (SCNSL)
|
January 22, 2019 | Phase 1 |
| NCT02309515 | Mayo Clinic|National Cancer Institute (NCI) |
Monoclonal B-Cell Lymphocytosis|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma
|
June 11, 2015 | Phase 2 |
| NCT01049945 | Mayo Clinic |
Refractory Multiple Myeloma
|
February 2010 | Phase 1|Phase 2 |
| NCT01750983 | M.D. Anderson Cancer Center |
Advanced Cancers
|
March 2013 | Phase 1 |
| NCT01754870 | University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc. |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)
|
November 2013 | Phase 2 |
| NCT00884546 | Bristol-Myers Squibb|Exelixis |
Advanced Cancer, Various, NOS
|
July 2009 | Phase 1 |
| NCT00840931 | H. Lee Moffitt Cancer Center and Research Institute|Celgene |
Leukemia
|
February 2, 2009 | Phase 1 |
| NCT02916771 | Dana-Farber Cancer Institute|Celgene|Takeda |
Smoldering Multiple Myeloma
|
October 2016 | Phase 2 |
| NCT01178814 | Columbia University|Celgene Corporation |
Myelodysplastic Syndrome
|
July 2010 | Phase 2 |
| NCT01927718 | M.D. Anderson Cancer Center|Celgene Corporation |
Myeloma
|
January 2014 | Not Applicable |
| NCT04653246 | Jacob Laubach|Sanofi|Dana-Farber Cancer Institute |
Multiple Myeloma|Newly Diagnosed Multiple Myeloma (NDMM)|Autologous Stem Cell Transplant
|
July 13, 2021 | Phase 2 |
| NCT05556616 | Takeda |
Multiple Myeloma
|
October 27, 2022 | Phase 1 |
| NCT00665652 | Dartmouth-Hitchcock Medical Center|Celgene Corporation |
Neuropathy|Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
|
April 2008 | Phase 2 |
| NCT02076009 | Janssen Research & Development, LLC |
Multiple Myeloma
|
May 23, 2014 | Phase 3 |
| NCT00419250 | Celgene |
Chronic Lymphocytic Leukemia|Leukemia, B-Cell, Chronic
|
December 1, 2006 | Phase 1 |
| NCT03118466 | Massachusetts General Hospital|Celgene |
AML
|
September 25, 2017 | Phase 2 |
| NCT02875067 | NYU Langone Health|Merck Sharp & Dohme LLC |
Relapsed Hodgkin Lymphoma|Relapsed Non-Hodgkin Lymphoma
|
August 29, 2016 | Phase 1|Phase 2 |
| NCT00179738 | Celgene Corporation|Prologue Research International|Celgene |
Prostate Cancer
|
April 2005 | Phase 2 |
| NCT00352001 | Mikkael Sekeres MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center |
Leukemia|Myelodysplastic Syndromes
|
May 2006 | Phase 1|Phase 2 |
| NCT03003520 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
February 28, 2017 | Phase 2 |
| NCT00689936 | Celgene |
Multiple Myeloma
|
August 21, 2008 | Phase 3 |
| NCT02415413 | PETHEMA Foundation|Celgene Corporation|Amgen |
Smoldering Multiple Myeloma
|
May 2015 | Phase 2 |
| NCT02005289 | Ohio State University Comprehensive Cancer Center|MorphoSys AG |
Contiguous Stage II Small Lymphocytic Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma
|
January 17, 2014 | Phase 2 |
| NCT00227591 | National Cancer Institute (NCI) |
Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis
|
December 2005 | Phase 2 |
| NCT01850524 | Millennium Pharmaceuticals, Inc.|Takeda |
Multiple Myeloma
|
May 17, 2013 | Phase 3 |
| NCT00474188 | Celgene Corporation|Celgene |
Diffuse Large B-cell Lymphoma
|
May 2007 | Phase 2 |
| NCT00055562 | Celgene Corporation|Celgene |
Melanoma|Neoplasm Metastasis
|
January 2003 | Phase 2|Phase 3 |
| NCT02219178 | Cancer Trials Ireland |
Multiple Myeloma
|
November 2014 | Phase 2 |
| NCT00091260 | Vaishali Sanchorawala|Celgene Corporation|Boston Medical Center |
Multiple Myeloma
|
January 2004 | Phase 2 |
| NCT04435743 | Ruijin Hospital |
Non-hodgkin Lymphoma,B Cell
|
November 1, 2019 | |
| NCT02038153 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission
|
December 2013 | Phase 1|Phase 2 |
| NCT05091372 | M.D. Anderson Cancer Center |
Myeloma Multiple
|
April 30, 2022 | Phase 2 |
| NCT01038388 | Emory University|Merck Sharp & Dohme LLC|Celgene Corporation |
Multiple Myeloma
|
January 15, 2010 | Phase 1 |
| NCT02705638 | Mayo Clinic|Celgene Corporation |
Immunoglobulin G Subclass 4 Related Disease|IgG4-related Disease|Autoimmune Pancreatitis|IgG4-related Sclerosing Cholangitis|Retroperitoneal Fibrosis
|
April 2016 | Phase 1 |
| NCT04717700 | Ida Bruun Kristensen|Karyopharm Therapeutics Inc|Odense Patient Data Explorative Network|Odense University Hospital |
Multiple Myeloma
|
August 18, 2021 | Phase 2 |
| NCT01021423 | Celgene |
Mantle Cell Lymphoma|Non-Hodgkin´s Lymphoma
|
April 1, 2010 | Phase 3 |
| NCT02802163 | H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen |
Multiple Myeloma
|
June 2017 | Phase 1|Phase 2 |
| NCT05257083 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 2022 | Phase 3 |
| NCT02561273 | University of Nebraska|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma
|
October 2015 | Phase 1|Phase 2 |
| NCT01644799 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Gilead Sciences|Celgene Corporation |
Recurrent Follicular Lymphoma
|
July 2013 | Phase 1 |
| NCT01254578 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK+T-Cell Lymphoma|Alkylating Agent-Related Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Post-Transplant Lymphoproliferative Disorder|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia+Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Richter Syndrome|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia
|
November 24, 2010 | Phase 1 |
| NCT00410605 | National Cancer Institute (NCI) |
Multiple Myeloma in Relapse|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
November 2006 | Phase 2 |
| NCT01919086 | Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.|Hartford Hospital |
Multiple Myeloma (MM)
|
August 2013 | Phase 2 |
| NCT01545804 | National Taiwan University Hospital |
Liver Cancer
|
August 2011 | Phase 2 |
| NCT02341014 | Memorial Sloan Kettering Cancer Center|University of Nebraska |
T-cell Lymphomas|Relapsed or Refractory
|
January 2015 | Phase 1|Phase 2 |
| NCT00891384 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
Multiple Myeloma
|
April 1, 2009 | Phase 3 |
| NCT00633594 | SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene |
Mantle Cell Lymphoma
|
June 2008 | Phase 1|Phase 2 |
| NCT00609869 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation |
Lymphocytic Leukemia|Mantle Cell Lymphoma
|
October 2007 | Phase 2 |
| NCT00495872 | M.D. Anderson Cancer Center |
Solid Tumors
|
June 2007 | Phase 1 |
| NCT03651128 | Celgene |
Multiple Myeloma
|
April 16, 2019 | Phase 3 |
| NCT01743859 | University of Colorado, Denver|Celgene |
Acute Myeloid Leukemia
|
December 6, 2012 | Phase 2 |
| NCT03379051 | TG Therapeutics, Inc.|James P. Wilmot Cancer Center |
Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma
|
March 27, 2018 | Phase 1|Phase 2 |
| NCT01749969 | Sanofi |
Plasma Cell Myeloma
|
February 6, 2013 | Phase 1 |
| NCT01686386 | Gruppo Italiano Studio Linfomi |
Multiple Myeloma
|
February 2010 | Phase 1|Phase 2 |
| NCT00902915 | Austrian Forum Against Cancer |
Multiple Myeloma Light Chain Induced Renal Insufficiency
|
May 2009 | Phase 2 |
| NCT05100862 | BeiGene |
Relapsed+Refractory Follicular Lymphoma|Marginal Zone Lymphoma
|
March 10, 2022 | Phase 3 |
| NCT04460248 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 22, 2020 | Phase 2 |
| NCT03605056 | Peng Liu|Chipscreen Biosciences, Ltd.|Shanghai Zhongshan Hospital |
Multiple Myeloma
|
July 31, 2018 | Phase 2 |
| NCT00738829 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene Corporation|Roche Pharma AG |
Leukemia, Lymphocytic, Chronic, B-Cell
|
October 2008 | Phase 1|Phase 2 |
| NCT02446236 | Hackensack Meridian Health |
Mantle Cell Lymphoma
|
June 18, 2015 | Phase 1 |
| NCT01723839 | Hackensack Meridian Health|Celgene Corporation |
Chronic Lymphocytic Leukemia (CLL)
|
February 22, 2012 | Phase 2 |
| NCT00064974 | Celgene Corporation|Celgene |
Myelodysplastic Syndromes
|
June 2003 | Phase 2 |
| NCT01639898 | University Hospital, Limoges|Ministry of Health, France|Celgene Corporation |
POEMS Syndrome
|
July 2012 | Phase 2 |
| NCT03289299 | International Myeloma Foundation|Amgen|Janssen Scientific Affairs, LLC|Celgene|Trevie, Inc. |
Smoldering Multiple Myeloma
|
May 25, 2018 | Phase 2 |
| NCT02353468 | University of Colorado, Denver |
Refractory Plasma Cell Myeloma
|
December 2009 | Phase 2 |
| NCT00975806 | Celgene |
Renal Cell Carcinoma
|
September 1, 2009 | Phase 1|Phase 2 |
| NCT04792502 | Brown University|Genentech, Inc. |
Follicular Lymphoma|Marginal Zone Lymphoma|B-cell Lymphoma
|
July 14, 2022 | Phase 2 |
| NCT03000634 | University of Arkansas |
Multiple Myeloma
|
May 2017 | Phase 2 |
| NCT03269136 | Pfizer |
Multiple Myeloma
|
November 29, 2017 | Phase 1 |
| NCT01556477 | Nordic MDS Group |
Myelodysplastic Syndrome|Acute Myelogenous Leukemia
|
March 2012 | Phase 2 |
| NCT03556332 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Multiple Myeloma
|
July 2, 2018 | Phase 2 |
| NCT00535873 | M.D. Anderson Cancer Center|Celgene |
Leukemia|CLL|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
October 2007 | Phase 2 |
| NCT02375555 | Dana-Farber Cancer Institute|Bristol-Myers Squibb |
Multiple Myeloma
|
May 7, 2015 | Phase 2 |
| NCT01936532 | Nantes University Hospital |
Newly Diagnosed Multiple Myeloma
|
November 12, 2014 | Phase 2 |
| NCT01373294 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation |
Bladder Cancer
|
November 30, 2011 | Phase 2 |
| NCT02886065 | Massachusetts General Hospital|Celgene|OncoPep, Inc. |
Smoldering Multiple Myeloma
|
November 2016 | Phase 1 |
| NCT01711554 | National Cancer Institute (NCI) |
Recurrent Neuroblastoma|Refractory Neuroblastoma
|
February 4, 2013 | Phase 1 |
| NCT04627753 | Kim, Seok Jin|Celltrion|Samyang Biopharmaceuticals Corporation|Samsung Medical Center |
Primary CNS Lymphoma
|
November 2, 2020 | Phase 2 |
| NCT02112175 | Celgene |
Multiple Myeloma
|
April 30, 2014 | Phase 3 |
| NCT05260619 | Seoul National University Bundang Hospital|Samyang BioPharm |
Central Nervous System Lymphoma
|
April 1, 2022 | Phase 2 |
| NCT01731886 | Columbia University |
Multiple Myeloma
|
September 2012 | Phase 4 |
| NCT04214626 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma
|
January 2, 2020 | Phase 2 |
| NCT01355705 | Michaela Liedtke|Celgene Corporation|Stanford University |
Multiple Myeloma
|
August 2011 | Phase 1|Phase 2 |
| NCT05598580 | First Affiliated Hospital of Zhejiang University |
HIV Infections
|
November 2022 | Phase 4 |
| NCT03359460 | Brian Jonas|Pharmacyclics LLC.|Celgene|National Cancer Institute (NCI)|University of California, Davis |
Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Refractory High Risk Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Therapy-Related Myelodysplastic Syndrome
|
December 1, 2017 | Phase 1 |
| NCT03558750 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb |
Recurrent Central Nervous System Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Central Nervous System Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
June 14, 2018 | Phase 1 |
| NCT02030483 | Weill Medical College of Cornell University|Celgene Corporation|Pfizer |
Multiple Myeloma
|
February 2014 | Phase 1 |
| NCT03641456 | Sun Yat-sen University |
Myeloma|Newly Diagnosed|High Risk
|
September 25, 2020 | Phase 2 |
| NCT02600897 | Hoffmann-La Roche |
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
March 23, 2016 | Phase 1 |
| NCT04923893 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 19, 2021 | Phase 3 |
| NCT01724177 | Celgene |
Adult T-Cell Leukemia-Lymphoma
|
November 12, 2012 | Phase 2 |
| NCT01038635 | M.D. Anderson Cancer Center|Celgene |
Leukemia
|
December 2009 | Phase 1|Phase 2 |
| NCT01816971 | University of Chicago|National Cancer Institute (NCI) |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma
|
January 2013 | Phase 2 |
| NCT00847639 | Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Celgene Corporation |
Multiple Myeloma
|
February 2009 | Phase 2 |
| NCT02441686 | Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene |
Multiple Myeloma
|
December 2015 | Phase 2 |
| NCT04430894 | Massachusetts General Hospital|Amgen|Sanofi |
Multiple Myeloma
|
July 10, 2020 | Phase 2 |
| NCT02145598 | Dr. med. Lars-Olof Muegge|University of Jena |
Multiple Myeloma
|
August 2013 | Phase 2|Phase 3 |
| NCT00179673 | Celgene Corporation|Prologue Research International|Celgene |
Non-Hodgkins Lymphoma
|
August 2005 | Phase 2 |
| NCT01916252 | PETHEMA Foundation|Janssen, LP|Celgene|Pierre Fabre Medicament |
Multiple Myeloma
|
September 2013 | Phase 3 |
| NCT00046735 | Celgene |
Neoplasms
|
June 1, 2002 | Phase 1 |
| NCT04680052 | Incyte Corporation |
Follicular Lymphoma|Marginal Zone Lymphoma
|
April 15, 2021 | Phase 3 |
| NCT02492750 | Mayo Clinic|National Cancer Institute (NCI) |
Indolent Plasma Cell Myeloma|Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma
|
April 2016 | Phase 1 |
| NCT00628238 | Chronic Lymphocytic Leukemia Research Consortium|Celgene Corporation |
Chronic Lymphocytic Leukemia|CLL|Untreated|Front-line|First-Line|Initial Therapy
|
February 2008 | Phase 2 |
| NCT04084626 | Beijing Friendship Hospital |
EBV Infection
|
September 15, 2019 | Phase 3 |
| NCT00860457 | Georgetown University|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
February 2008 | Phase 2 |
| NCT02128061 | The Lymphoma Academic Research Organisation|Centre Henri Becquerel |
Diffuse Large B Cell Lymphoma
|
August 2014 | Phase 3 |
| NCT03631043 | M.D. Anderson Cancer Center |
Smoldering Plasma Cell Myeloma
|
December 21, 2018 | Early Phase 1 |
| NCT04566328 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma
|
October 27, 2020 | Phase 3 |
| NCT05449548 | Peking Union Medical College Hospital |
Oral Ulcer
|
August 1, 2022 | Not Applicable |
| NCT02880228 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
September 16, 2016 | Phase 2 |
| NCT02636322 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma Unclassifiable
|
March 29, 2016 | Phase 2 |
| NCT01465230 | Yale University|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
March 2012 | Phase 2 |
| NCT00445484 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
January 2007 | Phase 2 |
| NCT01681537 | Massachusetts General Hospital |
Acute Myelogenous Leukemia
|
September 2012 | Phase 1 |
| NCT05344833 | University of Illinois at Chicago |
Multiple Myeloma
|
December 2022 | Phase 2 |
| NCT01002755 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Fatigue|Fever|Hypogammaglobulinemia|Lymphadenopathy|Lymphocytosis|Night Sweats|Paraproteinemia|Small Lymphocytic Lymphoma|Thrombocytopenia
|
January 19, 2010 | Phase 2 |
| NCT01703364 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene |
CLL|Chronic Lymphocytic Leukemia
|
June 2012 | Phase 1|Phase 2 |
| NCT00057616 | Celgene|ICON Clinical Research |
Melanoma|Neoplasm Metastasis
|
October 1, 2002 | Phase 3 |
| NCT01400685 | Massachusetts General Hospital|Dana-Farber Cancer Institute |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B Chronic Lymphocytic Leukemia
|
December 2012 | Phase 1 |
| NCT00424229 | Groupe Francophone des Myelodysplasies |
Myelodysplastic Syndromes
|
October 2006 | Phase 2 |
| NCT02312102 | Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. |
Myelodysplastic Syndrome|Acute Myeloid Leukemia
|
February 2015 | Phase 1 |
| NCT00729638 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Mayo Clinic|Memorial Sloan Kettering Cancer Center|Medical College of Wisconsin |
Multiple Myeloma
|
June 2008 | Phase 1 |
| NCT03901963 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2019 | Phase 3 |
| NCT02280525 | M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation |
Leukemia
|
March 5, 2015 | Phase 1 |
| NCT02659293 | University of Chicago |
Multiple Myeloma
|
April 26, 2016 | Phase 3 |
| NCT01501370 | Tiziana Marangon|University of Turin, Italy |
Multiple Myeloma
|
January 2012 | Phase 2 |
| NCT00396045 | University of Turin, Italy |
Multiple Myeloma
|
January 2005 | Phase 1|Phase 2 |
| NCT00910858 | Celgene Corporation|Celgene |
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
|
January 2005 | Phase 1|Phase 2 |
| NCT01537861 | Washington University School of Medicine |
Multiple Myeloma
|
June 2012 | Early Phase 1 |
| NCT00096044 | Roswell Park Cancer Institute|Celgene |
Leukemia
|
March 2004 | Phase 2 |
| NCT04892264 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
June 4, 2021 | Phase 1|Phase 2 |
| NCT02992522 | Beth Christian|Celgene|Genentech, Inc.|Ohio State University Comprehensive Cancer Center |
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma
|
February 21, 2017 | Phase 1 |
| NCT00729118 | Ohio State University Comprehensive Cancer Center|Merck Sharp & Dohme LLC |
Multiple Myeloma|Plasma Cell Neoplasm
|
September 26, 2008 | Phase 1 |
| NCT05335018 | Seoul National University Hospital |
Relapsed+Refractory Diffuse Large B Cell Lymphoma
|
May 30, 2022 | Phase 2 |
| NCT01111903 | ARCAGY+ GINECO GROUP |
Ovarian Cancer Recurrent
|
May 2009 | Phase 1|Phase 2 |
| NCT02523040 | Dana-Farber Cancer Institute|Celgene |
Langerhans Cell Histiocytosis (LCH)|Histiocytoses Erdheim-chester Disease|Histiocytic Sarcoma (HS)
|
August 2015 | Phase 2 |
| NCT03591744 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Leukemia
|
October 25, 2018 | Phase 1 |
| NCT05105412 | National Health Research Institutes, Taiwan|National Taiwan University Hospital|Chang Gung Memorial Hospital|National Cheng-Kung University Hospital|China Medical University Hospital |
Peripheral T-cell Lymphomas (PTCL)
|
October 31, 2021 | Phase 1|Phase 2 |
| NCT01088048 | Gilead Sciences |
Indolent Non-Hodgkin´s Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma
|
March 25, 2010 | Phase 1 |
| NCT03795571 | The First Affiliated Hospital with Nanjing Medical University |
Diffuse Large B-cell Lymphoma Recurrent|Diffuse Large B Cell Lymphoma Refractory
|
January 1, 2019 | Phase 1 |
| NCT05205252 | Epizyme, Inc. |
Relapsed+Refractory
|
December 22, 2021 | Phase 1|Phase 2 |
| NCT01303965 | Sherif S. Farag|Celgene Corporation|Indiana University |
Multiple Myeloma
|
February 7, 2011 | Phase 1|Phase 2 |
| NCT04802356 | PETHEMA Foundation|GlaxoSmithKline |
Multiple Myeloma
|
April 7, 2021 | Phase 2 |
| NCT04423926 | The First Affiliated Hospital with Nanjing Medical University |
PTCL, NOS|AITL|ALK- ALCL|Phase III-IV ALK&addition; ALCL|EATL
|
June 10, 2020 | Phase 1|Phase 2 |
| NCT02538198 | Memorial Sloan Kettering Cancer Center |
Plasma Cell Myeloma
|
August 31, 2015 | Phase 2 |
| NCT00988208 | Celgene |
Prostate Cancer
|
November 11, 2009 | Phase 3 |
| NCT00691704 | Cristina Gasparetto|Celgene Corporation|Duke University |
Multiple Myeloma
|
August 2008 | Phase 2 |
| NCT00305812 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 13, 2005 | Phase 2 |
| NCT01891643 | Bristol-Myers Squibb|Abbott |
Newly Diagnosed, Previously Untreated Multiple Myeloma
|
September 30, 2013 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL ( 186.38 mM ; Need ultrasonic)
H 2 O : 0.1 mg/mL ( 0.37 mM ; Need ultrasonic)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.7276 mL | 18.6379 mL | 37.2759 mL |
| 5 mM | 0.7455 mL | 3.7276 mL | 7.4552 mL |
| 10 mM | 0.3728 mL | 1.8638 mL | 3.7276 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
*
All of the co-solvents are available by MCE.
References
- [1] Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.
- [2] Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.
- [3] Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36.
- [4] Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35.
- [5] Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.